Accepted Manuscript

Title: Anti-inflammatory functions of glucocorticoid-induced genes

Author: Andrew R. Clark

PII: S0303-7207(07)00184-0
DOI: doi:10.1016/j.mce.2007.04.013
Reference: MCE 6649

To appear in: *Molecular and Cellular Endocrinology*

Received date: 9-3-2007
Accepted date: 25-4-2007

Please cite this article as: Clark, A.R., Anti-inflammatory functions of glucocorticoid-induced genes, *Molecular and Cellular Endocrinology* (2007), doi:10.1016/j.mce.2007.04.013

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Anti-inflammatory functions of glucocorticoid-induced genes.

Andrew R. Clark

Kennedy Institute of Rheumatology Division

Imperial College London

1 Aspenlea Road

Hammersmith

London W6 8LH

United Kingdom

Email andy.clark@imperial.ac.uk

Phone +44 208 383 4430

Fax +44 208 383 4496

Abbreviations: AnxA1, annexin A1; AP1, activating protein 1; ARE, adenylate/uridylate-rich element; AREBP, ARE binding protein; C/EBP, CCAAT/enhancer binding protein; CCL, chemokine (C-C motif) ligand; CLE0, conserved lymphokine element 0; COX-2, cyclooxygenase 2; CSF2, colony stimulating factor 2; CXCL, chemokine (C-X-C motif) ligand; dc, dendritic cell; Dok-1, downstream of tyrosine kinase 1; DUSP, dual specificity phosphatase; ENaC, epithelial sodium channel; ERK, extracellular signal regulated kinase; Fox, forkhead box transcription factor; FPR, formyl peptide receptor; GC, glucocorticoid; GILZ, GC-induced leucine zipper protein; GR, GC receptor; GR^{dim}, dimerization defective GR mutant; GRE, GC response element; ICAM, intracellular adhesion molecule; IκB, inhibitor of NFκB; IL, interleukin; LZ, leucine zipper; MAPK, mitogen activated protein kinase; MKP, MAPK phosphatase; NFκB, nuclear factor of κB; PEPCK, phosphoenolpyruvate carboxykinase; PI3K, phosphatidylinositol 3 kinase; RA, rheumatoid arthritis; siRNA, short interfering RNA; SLAP, src-like adaptor protein; STAT, signal transducer and activator of transcription; TAT, tyrosine aminotransferase; TNF, tumor necrosis factor; TTP, tristetraprolin; UTR, untranslated region

ABSTRACT.

There is a broad consensus that glucocorticoids (GCs) exert anti-inflammatory effects largely by inhibiting the function of nuclear factor κ B (NF κ B) and consequently the transcription of pro-inflammatory genes. In contrast, side-effects are thought to be largely dependent on GC-induced gene expression. Biochemical and genetic evidence suggests that the positive and negative effects of GCs on transcription can be uncoupled from one another. Hence, novel GC-related drugs that mediate inhibition of NF κ B but do not activate gene expression are predicted to retain therapeutic effects but cause fewer or less severe side effects. Here we critically re-examine the evidence in favor of the consensus, binary model of GC action and discuss conflicting evidence, which suggests that anti-inflammatory actions of GCs depend on the induction of anti-inflammatory mediators. We propose an alternative model, in which GCs exert anti-inflammatory effects at both transcriptional and post-transcriptional levels, both by activating and inhibiting expression of target genes. The implications of such a model in the search for safer anti-inflammatory drugs are discussed.

INTRODUCTION.

The powerful anti-inflammatory actions of glucocorticoid hormones (GCs) were discovered in the late 1940s by Philip Hench and his collaborators, who were attempting to treat the chronic and debilitating inflammatory disease, rheumatoid arthritis (RA). Within little more than a year the newly isolated GC cortisone had been licensed by the United States Food and Drug Administration, several thousand RA patients around the world had been treated with it, and the Nobel Prize for Physiology or Medicine (1950) had been awarded to Dr Hench and his collaborators, Tadeus Reichstein and Edward Kendall. In large part, this reflects the paucity of anti-inflammatory treatments then available, and the almost miraculous beneficial effects of cortisone. Since that time synthetic GCs have become a mainstay in the treatment of diseases such as rheumatoid arthritis, inflammatory bowel disease, asthma, multiple sclerosis and many others. However, severe side-effects of GCs have been recognised from the very beginning, and were even detailed in Philip Hench's Nobel prize lecture (Hench, 1950). For decades, clinicians and basic scientists have been fascinated by GCs because they are at the same time amongst the most useful and the most problematic compounds in the pharmacopoeia. If their desired anti-inflammatory effects could somehow be uncoupled from their side effects the clinical benefits would be enormous. It has become widely accepted that such uncoupling might be achieved through separation of activatory and inhibitory effects of glucocorticoids on gene expression. Here this supposition will be re-examined from a critical viewpoint, which emphasizes the gaps in our current knowledge of GC action and the potential roles of GC-induced genes in the inhibition of inflammation.

ANTI-INFLAMMATORY ACTION OF GLUCOCORTICOIDS: THE CURRENT PARADIGM.

Effects of GCs on gene expression are mediated by the GC receptor (GR), a member of a large family of nuclear hormone receptor transcription factors (Newton, 2000; Rhen and Cidlowski, 2005). When activated by ligand, GR is released from a multiprotein complex in the cytoplasm and translocates to the nucleus. Once there it can positively regulate gene expression by dimerizing and binding to palindromic GC response elements (GREs) in the promoters of target genes. Such a sequence exists in the promoter of tyrosine aminotransferase (TAT), a metabolic enzyme. Disturbances of metabolism are amongst the important side effects of prolonged treatment with synthetic GCs, and may be caused by the upregulation of TAT and other genes such as phosphoenolpyruvate carboxykinase (PEPCK). GR can also interact in a dimerization-independent manner with other transcription factors such as nuclear factor κ B (NF κ B) and activating protein 1 (AP1), impairing their ability to activate gene expression, a process known as transrepression (throughout this article, “transrepression” is used in the strict sense of an inhibitory process involving direct or indirect physical interaction of GR with a target transcription factor). The molecular details of this mechanism are hotly debated as described elsewhere in this issue, and do not need to be explored again here. Most importantly, transrepression is both rapid and direct (mediated by pre-existing factors). NF κ B is activated by most pro-inflammatory stimuli and, although its role is not restricted to the inflammatory response, it is important for the expression of many inflammatory mediators (Doyle and O'Neill, 2006; Grivennikov et al., 2006). For this reason its inhibition is, in principle, a powerful anti-inflammatory mechanism. Transrepression of AP1 may also contribute to the inhibition of anti-inflammatory gene expression, but its mechanism does not appear to be identical (Bladh et al., 2005).

The dimerization of GR is dependent on a short stretch of five amino acids known as the D loop, lying within the second zinc finger (Dahlman-Wright et al., 1993; Dahlman-Wright et al., 1991). Mutation of these residues strongly impaired (but did not abolish) binding of GR as a dimer to simple palindromic GREs in vitro. Mutation of alanine 458 to threonine within the D loop created a mutant (known as GR^{dim}), which poorly activated GRE-dependent reporters but retained the ability to repress AP1-dependent (Heck et al., 1997; Heck et al., 1994) or NFκB-dependent reporters (Reichardt et al., 2001). In an elegant series of experiments, a mouse “knock-in” strain was generated, replacing endogenous GR with the GR^{dim} mutant (Reichardt et al., 1998; Reichardt et al., 2001; Tuckermann et al., 1999). In macrophages or T cells expressing only GR^{dim}, the synthetic GC dexamethasone (dex) retained its ability to suppress tumor necrosis factor (TNF), interleukin (IL)-1β, IL-2, IL-6 and cyclooxygenase 2 (COX-2) gene expression (Reichardt et al., 2001). Dex exerted comparable therapeutic effects on PMA-induced skin inflammation or LPS-induced endotoxemia in wild type and mutant mice. On the other hand TAT and PEPCK were poorly induced by dex in the GR^{dim} mouse.

To a great extent these observations form the basis of the current consensus: that anti-inflammatory effects of GCs are largely mediated by transrepression, whereas side effects are largely mediated by activation of gene expression. From this premise it follows that uncoupling of the gene-activating and gene-suppressing properties of GR should yield clinical benefits. In other words “dissociated” GCs that selectively mediate transrepression rather than transactivation should show equivalent anti-inflammatory properties whilst causing less severe side effects (Belvisi et al., 2001; Rosen and Miner, 2005; Schacke et al., 2005). A simple course of action suggests itself for the discovery of dissociated GCs. Candidate compounds could be tested for their ability to inhibit a reporter controlled by multiple NFκB sites and to activate a reporter controlled by multiple GREs. Successful compounds should, of

course, pass the first test and fail the second. First generation dissociated GCs have been identified in this manner (Heck et al., 1997; Vanden Berghe et al., 1999; Vayssiere et al., 1997).

RESERVATIONS.

The complexity of GC action.

An important concern is that the standard model does poor justice to the great complexity of transcriptional control by GR. In the first place, the majority of genes directly activated by GCs do not appear to be controlled through conventional GREs. For example a microarray-based study of murine T lymphoma cells identified 44 direct GC targets (ie genes whose upregulation by GC was not prevented by cycloheximide). Of these, only five contained matches to the GRE consensus within 8 kb of the transcription start site (Chen et al., 2003). On the other hand, an *in silico* approach identified 565 exact matches to the GRE consensus in the human genome (Horie-Inoue et al., 2006). Of these, only 26 were located within 10 kb of transcribed genes. In DU145 (prostate cancer) cells chromatin immunoprecipitation analysis showed association of GR with only two of these putative regulatory sites, but the adjacent genes were not upregulated by GC. These investigations, unbiased by prior expectation, suggest that GCs tend to regulate gene expression through sequence elements that are not classical, consensus GREs.

Typically, GC responsive regions of *bona fide* GC-regulated genes are rather extended and contain binding sites for multiple transcription factors but only poor matches to the GRE consensus (Wang et al., 2004). A good example is the PEPCK gene, which contains two GR binding sites with limited homology to the GRE consensus. Efficient induction of gene expression by GCs requires binding of additional transcription factors to accessory sites within an extended, composite response element (Cassuto et al., 2005; Imai et al., 1990; Mitchell et al., 1994; Yamada et al., 1999). This complex element mediates the coordinate regulation of PEPCK expression by several agonists, including GCs,

insulin and retinoic acid. Composite GC responsive regions have been described in the promoters of tyrosine aminotransferase (Grange et al., 2001; Grange et al., 1989; Roux et al., 1995; Sassi et al., 1998) proliferin (Diamond et al., 1990), α 1-acid glycoprotein (Alam et al., 1993; Nishio et al., 1993; Savoldi et al., 1997), the cyclin-dependent kinase inhibitor p21^{waf1/cip1} (Cha et al., 1998; Cram et al., 1998), β 1-adrenergic receptor (Tseng et al., 2001), glucose-6-phosphate transporter (Kallwellis-Opara et al., 2003), pyruvate dehydrogenase kinase 4 (Kwon et al., 2004), monoamine oxidase (Manoli et al., 2005; Ou et al., 2006), β -casein (Rosen et al., 1998; Wyszomierski and Rosen, 2001) and others. Although GR alone has low affinity for sites that diverge from the GRE consensus, high affinity binding and transcriptional activation can be restored in the presence of multiple sub-optimal GR binding sites such as half GREs (Lechner et al., 1997) or adjacent binding sites for other transcription factors (Guido et al., 1996; Morin et al., 2000; Stafford et al., 2001; Strahle et al., 1988). Recruitment to such sites is thought to be mediated by both protein-DNA interactions and protein-protein interactions of GR with other transcription factors. GR has been shown to cooperate with transcription factors of many different classes, including the zinc finger transcription factor, stimulatory protein 1 (Sp1) (Manoli et al., 2005; Marinovic et al., 2002; Ou et al., 2006), homeobox proteins (Subramaniam et al., 2003), ets-related proteins (Aittomaki et al., 2000; Aurrekoetxea-Hernandez and Buetti, 2004; Mullick et al., 2001), interferon response factors (Jiang et al., 2004), helix-loop-helix factors (Jiang et al., 2004; Tseng et al., 2001), members of the CCAAT/enhancer-binding protein (C/EBP), forkhead box (Fox) and signal transducer and activator of transcription (STAT) families, and even NF κ B itself (Hofmann and Schmitz, 2002).

Functional interactions of GR with members of the STAT family are well reviewed elsewhere (Rogatsky and Ivashkiv, 2006). The STATs mediate transcriptional activation in response to cytokine signalling, and exert pleiotropic effects on immunity and inflammation (Brierley and Fish, 2005).

Expression of β -casein is synergistically regulated by prolactin-activated STAT5 and GC-activated GR (Kabotyanski et al., 2006; Lechner et al., 1997; Stocklin et al., 1996; Stoecklin et al., 1999; Wyszomierski and Rosen, 2001). The latter regulates transcription via multiple GRE half-sites, and is dependent on STAT5 for recruitment to the β -casein 5' region. A functional interaction between GR and STAT5 is also implicated in the cooperative regulation of toll-like receptor 2 (TLR2) expression by GC and TNF (Hermoso et al., 2004). In liver, GR is recruited to STAT5 regulated genes such as insulin-like growth factor 1, and is required for normal post-natal growth. Importantly, this GR-mediated transcriptional control is intact in liver cells expressing only GR^{dim} (Tronche et al., 2004). In a similar fashion, STAT3 and GR can physically interact and cooperate to activate promoters containing either STAT or GR binding sites (De Miguel et al., 2003; Kordula and Travis, 1996; Lerner et al., 2003; Takeda et al., 1998; Zhang et al., 1997).

Three distinct mechanisms of functional interaction between GR and members of the C/EBP family of transcription factors have been described. Least direct of all, GCs can upregulate expression of C/EBPs, for example in muscle (Penner et al., 2002; Yang et al., 2005), liver (Cram et al., 1998; Gotoh et al., 1997; Matsuno et al., 1996; Ramos et al., 1996) or differentiating adipocytes (Hernandez et al., 2003; Shi et al., 2000). Secondly, GR can cooperate with C/EBP transcription factors to activate transcription through composite response elements such as those of α 1 acid glycoprotein (Alam et al., 1993; Chang et al., 1998; Savoldi et al., 1997), PEPCK (Arizmendi et al., 1999; Crosson and Roesler, 2000; Yamada et al., 1999) and β casein genes (Wyszomierski and Rosen, 2001). Finally, GCs can enhance the function of C/EBP β . This process involves the phosphorylation of C/EBP β and exchange of associated coactivator/corepressor proteins, although it is unclear whether a direct interaction between GR and C/EBP β is required (Berg et al., 2005; Boruk et al., 1998; Wiper-Bergeron et al., 2003).

Several members of the Fox family of transcription factors have been shown to interact functionally with GR. Such interactions may be particularly significant to the regulation of carbohydrate metabolism, where GCs and insulin have opposing actions. Glucose 6 phosphatase (Nakae et al., 2001) pyruvate dehydrogenase kinase 4 (Furuyama et al., 2003; Kwon et al., 2004), glucose 6 phosphate transporter (Kallwellis-Opara et al., 2003) and insulin-like growth factor binding protein 1 (Yeagley et al., 2001) are cooperatively regulated by GR and FoxO transcription factors. Insulin causes inactivation of FoxOs via Akt-mediated phosphorylation, thereby antagonizing GC-induced gene expression. A similar mechanism may be relevant to the anti-inflammatory action of GCs (Asselin-Labat et al., 2005). IL2-induced, Akt-mediated phosphorylation of FoxO3 antagonizes the induction by GCs of glucocorticoid-induced leucine zipper (GILZ; see below).

Post-transcriptional gene regulation by GCs.

Endogenous GCs are upregulated by pro-inflammatory cytokines and play a critical role in the resolution of inflammation. To fulfil this function they must be able to suppress ongoing inflammatory responses. Transrepression is potentially a powerful mechanism for inhibiting inflammation, but an important limitation is that it can be effective only if GCs are present during the period of active transcription. For many inflammatory mediators the activation of transcription is highly transient and this window of opportunity is correspondingly narrow. In experimental settings GCs are capable of blocking gene expression even if added some time after a pro-inflammatory stimulus, whilst inhibitors of transcription are ineffective (Chivers et al., 2006; Lasa et al., 2002; Newton et al., 1998). There must therefore exist suppressive mechanisms that function at a post-transcriptional level. By definition these have nothing to do with transrepression, which can have no influence on pre-existing mRNAs.

In fact GCs have long been known to inhibit inflammatory gene expression at a post-transcriptional level, via destabilisation of mRNA or inhibition of translation (Ing, 2005; Stellato, 2004). Targets of such regulation include COX-2 (Chivers et al., 2006; Lasa et al., 2001; Newton et al., 1998; Ristimäki et al., 1996), TNF (Han et al., 1990; Kontoyiannis et al., 1999; Swantek et al., 1997), vascular endothelial growth factor (Gille et al., 2001), interferon β (Peppel et al., 1991), colony stimulating factor 2 (CSF2) (Bergmann et al., 2004; Tobler et al., 1992; Tran et al., 2005), IL-5 (Staples et al., 2003), IL-6 (Amano et al., 1993; Tobler et al., 1992), IL-1 α and -1 β (Amano et al., 1993; Lee et al., 1988), inducible nitric oxide synthase (Korhonen et al., 2002) and several chemokines (Berkman et al., 1995; Brach et al., 1992; Chang et al., 2001; Chaudhary and Avioli, 1996; Chivers et al., 2006; Mukaida et al., 1991; Poon et al., 1999; Stellato et al., 1999; Tobler et al., 1992). The majority of these mRNAs have in common the presence of adenylate/uridylate-rich elements (AREs) in their 3' untranslated regions (UTRs). AREs form specific binding sites for ARE-binding proteins (AREBPs) such as tristetraprolin (TTP), which function by recruiting components of the cellular mRNA degradation machinery and causing rapid destruction of target mRNAs (Carrick et al., 2004; Fenger-Gron et al., 2005; Guhaniyogi and Brewer, 2001; Kracht and Saklatvala, 2002; Lykke-Andersen and Wagner, 2005; Wilusz et al., 2001). ARE-AREBP complexes also mediate the post-transcriptional regulation of mRNA stability by signal transduction pathways. For example many ARE-containing inflammatory mRNAs are unstable in the absence of an appropriate stimulus, but are transiently stabilized following the activation of the p38 mitogen-activated protein kinase (MAPK) pathway (Clark et al., 2003; Dean et al., 2004), which brings about the phosphorylation and inactivation of TTP (Stoecklin et al., 2004). An unusual mechanism exists for the GC-induced destabilization of CCL2 (chemokine C-C motif ligand 2) mRNA. GCs can destabilize this transcript independently of ongoing transcription and translation via an element in the 5' UTR (Poon et al., 1999), which forms a direct target for ligand-activated GR (Dhawan et al., 2007). In almost every other case, post-transcriptional

effects of GCs on inflammatory gene expression are dependent on GC-induced gene expression. Therefore, in classical chase experiments to study mRNA stability, effects of GCs can be masked unless they are present for some time prior to the addition of the transcriptional inhibitor actinomycin D. As described below, GCs may influence pro-inflammatory gene expression by altering the expression of AREBPs, by modulating the activity of the signalling pathways that control them, or both. Post-transcriptional effects of GCs are easily overlooked, cannot be explained in terms of transrepression and scarcely feature in most reviews of GC action. However, a recent microarray-based study of global changes in gene expression suggests that such effects may account for at least 50% of GC-mediated changes in steady-state mRNA levels (Fan et al., 2006).

Evidence in favour of transrepression.

It is often stated as fact that GCs inhibit pro-inflammatory gene expression principally by means of transrepression. So much depends on this assertion that it is worth re-examining its basis in evidence. The most important supporting observation is that some anti-inflammatory effects of GCs are preserved in mice that express only a dimerization-defective form of GR (Reichardt et al., 2001). An important unanswered question is whether GC responses of the GR^{dim} mouse remain intact in more complex models of inflammatory disease than PMA-induced skin inflammation or LPS-induced endotoxemia. Another question is whether GR-mediated activation of gene expression is completely abolished by the mutation of a single amino acid within the GR dimerization domain. In transfected cells GR^{dim} is capable of inducing at least some GC target genes (Rogatsky et al., 2003), cooperative gene regulation by GCs and STAT5 is spared in the GR^{dim} mouse (Tronche et al., 2004), and at least one anti-inflammatory mediator is effectively induced by GCs in murine macrophages expressing only GR^{dim} (Abraham et al., 2006). In the absence of microarray data describing global transcriptional changes in cells expressing GR^{dim}, it is too early to conclude how broadly and how strongly the induction of gene expression by GCs is impaired, therefore it remains a strong possibility that this mutation does not

make a clear distinction between gene activatory and gene-suppressive effects of GCs *in vivo*. Other than the GR^{dim} mouse, we know of no murine genetic model supporting the assertion that transrepression is the only (or even principal) anti-inflammatory mechanism of GCs.

There is firm evidence that GR can transrepress NFκB, AP1 and other transcription factors, and plentiful, though sometimes contradictory, evidence concerning the molecular mechanisms involved. Neither of these constitutes proof that transrepression is the principal mechanism by which GCs inhibit pro-inflammatory gene expression. Several different elements would need to be established in the hypothetical case of a gene containing an NFκB site in its promoter. IL-8 (otherwise known as chemokine C-X-C motif ligand 8, CXCL8) is an archetypal GC-sensitive pro-inflammatory gene that is considered a target of transrepression, and is discussed as an illustrative example where appropriate.

GCs inhibit gene expression at the transcriptional level but not at the post-transcriptional level. Many pro-inflammatory mediators (including CXCL8) have both NFκB sites in their promoters and AREs in their 3' UTRs, and can be suppressed by GCs at both transcriptional and post-transcriptional levels. However, GC-induced changes in pro-inflammatory mRNA levels are often ascribed to transcriptional effects alone without formal supporting evidence, for example nuclear run-on and actinomycin D chase experiments. Transcriptional and post-transcriptional mechanisms are in no way mutually exclusive, and some individual genes have been shown to be suppressed by GCs at both levels in a single cell type (Lee et al., 1988; Newton et al., 1998; Stellato et al., 1999; Zitnik et al., 1994). In other cases data on the relative contributions of transcriptional and post-transcriptional mechanisms are contradictory. Dex did not strongly inhibit CXCL8 transcription in nuclear run-on experiments, but potently destabilized CXCL8 mRNA in bone marrow stromal cells, lung fibroblasts, epithelial cells or cell lines (Chang et al., 2001; Chaudhary and Avioli, 1996; Chivers et al., 2006; Tobler et al., 1992). In contrast, other

reports described dex-mediated inhibition of an CXCL8 promoter construct and a lack of effect of dex on CXCL8 mRNA stability (Edwards et al., 2005; Kwon et al., 1994).

Inhibitory effects of GC do not require de novo gene expression. In its strictest sense, transrepression is a rapid and direct mechanism that is mediated by pre-existing factors and does not require *de novo* gene expression. Consistent with this, the protein synthesis inhibitor cycloheximide (CHX) did not diminish the inhibitory effect of dex on expression of IL-6, intracellular adhesion molecule (ICAM)-1 or COX-2 mRNAs (De Bosscher et al., 1997; Wissink et al., 1998). In other studies, CHX blocked the GC-mediated suppression of urokinase plasminogen activator, COX-2 and CXCL8 mRNA (Chang et al., 2001; Chaudhary and Avioli, 1996; Chivers et al., 2006; Henderson and Kefford, 1993; Newton et al., 1998; Tobler et al., 1992). This implies that GC-induced gene expression is involved, and that transrepression is insufficient for gene suppression in some circumstances.

GC-dependent inhibition of gene expression is not accompanied by a global defect in NF κ B activation. Whereas other models invoke general inhibition of nuclear translocation or DNA binding of NF κ B, the transrepression model states that GCs inhibit NF κ B function at a level downstream of DNA binding. In some studies anti-inflammatory effects of GCs were not accompanied by changes in DNA-binding activity of NF κ B as measured by electrophoretic mobility shift assay (Brostjan et al., 1996; De Bosscher et al., 1997; Hofmann et al., 1998; Nissen and Yamamoto, 2000; Ray et al., 1997; Wissink et al., 1998). However, in other cases GCs were found to inhibit NF κ B activation as measured by the same assay (Eberhardt et al., 2002; Goppelt-Struebe et al., 2000; Kurata and Yamamoto, 1999; Kurokouchi et al., 2000; Ma et al., 2004; Mukaida et al., 1994; Vital et al., 2003). The latter observations are inconsistent with the transrepression model.

GCs do not inhibit the recruitment of NF κ B to the target promoter in vivo. Subtle variations in NF κ B core binding sequence and flanking residues can have a profound effect on regulatory activities (Doyle and O'Neill, 2006; Hoffmann et al., 2003; Leung et al., 2004), and binding of NF κ B to sites in

A Clark Anti-inflammatory functions of glucocorticoid-induced genes Page 15 of 53

chromatin may not be accurately reflected by binding to oligonucleotide probes *in vitro* (Grivennikov et al., 2006; Saccani et al., 2002). For these reasons it is important to show that GCs do not impair the interaction of NFκB with the relevant cognate site *in vivo*, an important proposition of the transrepression model. Accordingly, GCs did not inhibit binding of NFκB to the 5' regions of the chemokines CXCL1 and CXCL9 (Ogawa et al., 2005), ICAM-1 (Liden et al., 2000) or CXCL8 (De Bosscher et al., 2005; Luecke and Yamamoto, 2005; Nissen and Yamamoto, 2000). To our knowledge, effects of GCs on NFκB recruitment at other transrepressed genes have not been reported.

GC-dependent inhibition of gene expression is accompanied by recruitment of GR to the target promoter. Another central element of the transrepression model is that physical (direct or indirect) interaction between GR and NFκB mediates recruitment of GR to inflammatory promoters. Such recruitment has been demonstrated in very few examples, one of which is CXCL8 (Garside et al., 2004; Luecke and Yamamoto, 2005; Nissen and Yamamoto, 2000). In HeLa cells dexamethasone promoted recruitment of GR to the CXCL8 promoter and inhibited TNF-induced expression of CXCL8. In contrast the antagonistic ligand RU486 did neither (Garside et al., 2004), suggesting a causal link between GR recruitment and gene suppression. However, in at least one instance recruitment of GR to an inflammatory promoter occurred in the absence of transrepression (Luecke and Yamamoto, 2005; Nissen and Yamamoto, 2000). This observation raises the question of whether the recruitment of GR to NFκB sites is both necessary and sufficient for inhibition of gene expression.

GC-INDUCED ANTI-INFLAMMATORY MEDIATORS.

Inhibitor of NFκB α (IκBα).

In the absence of appropriate stimuli, NFκB components are held in the cytoplasm by interactions with inhibitors of NFκB (IκBs). Pro-inflammatory signaling pathways cause the degradation of IκB proteins and the release of NFκB, which then enters the nucleus to activate target genes. Two groups

independently identified the upregulation of I κ B α as a putative mechanism by which GCs could impair NF κ B function and inhibit expression of immune or inflammatory mediators (Auphan et al., 1995; Scheinman et al., 1995a; Scheinman et al., 1995b). A number of problems with this hypothesis have since been raised. In several different cell types the GC-induced upregulation of I κ B α either did not occur or was not sufficient to alter the degradation of I κ B α protein, and the nuclear translocation of NF κ B in response to pro-inflammatory stimuli (Adcock et al., 1999; Adcock et al., 1997; Auwardt et al., 1998; Brostjan et al., 1996; De Bosscher et al., 1997; Hofmann et al., 1998; Liden et al., 2000; Nissen and Yamamoto, 2000; Pruett et al., 2003; Ray et al., 1997; Wissink et al., 1998). As described above, inhibition of inflammatory gene expression could occur without apparent changes in NF κ B promoter occupancy (Liden et al., 2000; Luecke and Yamamoto, 2005). Repression of NF κ B function was not dependent on de novo gene expression {De Bosscher et al., 1997; Nissen and Yamamoto, 2000; Ogawa et al., 2005; Wissink et al., 1998). Novel GR agonists have been described, which enhanced I κ B α expression but did not exert anti-inflammatory effects (Heck et al., 1997). GCs efficiently repressed a chimeric transcription factor consisting of the yeast Gal4 DNA binding domain and the transcriptional activation domain of the NF κ B subunit p65 (De Bosscher et al., 1997; De Bosscher et al., 2005; Vanden Berghe et al., 1999). The nuclear localization and DNA binding activity of this fusion protein were not regulated by GCs.

All of these observations clearly establish that inhibition of NF κ B function *can* occur independently of I κ B α induction. However, they fall short of proving that I κ B α induction plays no part in the anti-inflammatory actions of GCs. I κ B α expression is tissue-specifically regulated, and is enhanced by GCs in several primary or transformed cell types (Almon et al., 2005; Auphan et al., 1995; Kang et al., 2006; Kurata and Yamamoto, 1999; Kurokouchi et al., 2000; Quan et al., 2000; Ramdas and Harmon, 1998; Scheinman et al., 1995a; Shames et al., 1998; Stojadinovic et al., 2006; Thiele et al., 1999). In

some cases GC treatment inhibited I κ B α degradation, nuclear translocation of p65 or formation of nuclear NF κ B complexes (Eberhardt et al., 2002; Goppelt-Strube et al., 2000; Kurata and Yamamoto, 1999; Kurokouchi et al., 2000; Ma et al., 2004; Mukaida et al., 1994; Vital et al., 2003). This is not consistent with a model in which GCs inhibit NF κ B only at a level downstream of DNA binding, although it does not conclusively prove that upregulation of I κ B α is critical. GR-mediated inhibition of NF κ B function through protein-protein interactions (classical transrepression) and through upregulation of inhibitory molecules such as I κ B α are, of course, not mutually exclusive mechanisms. I κ B α -mediated inhibitory effects of GC may be significant in particular tissues, and in the context of prolonged GC exposure. Mice lacking I κ B α have a severe inflammatory phenotype and die soon after birth (Beg et al., 1995; Chen et al., 2000; Klement et al., 1996), which is likely to complicate experiments to directly address the role of I κ B α in responses to GCs. The question might be best answered by studying GC responses in conditional and/or tissue-specific I κ B α knockouts.

The I κ B α promoter does not possess a typical palindromic GRE (Deroo and Archer, 2001) but does have a potential half-site located between two NF κ B elements (Heck et al., 1997). Dex induced only a twofold increase in I κ B α mRNA and protein in wild-type fibroblasts, and this increase did not occur in fibroblasts expressing GR^{dim} (Reichardt et al., 2001). The implication is that upregulation of I κ B α is dependent on dimerization of GR, although the detailed mechanism of gene regulation remains to be established.

DUSP1

Dual specificity phosphatase 1 (DUSP1) is the first described member of a large family of phosphatases that catalyse removal of phosphate from serine, threonine or tyrosine residues (Dickinson and Keyse, 2006; Liu et al., 2007; Theodosiou and Ashworth, 2002). It is expressed in response to GCs

A Clark Anti-inflammatory functions of glucocorticoid-induced genes Page 18 of 53

in a wide variety of cell types including mast cells (Kassel et al., 2001), monocytes or macrophages (Abraham et al., 2006; Aeberli et al., 2006; Bhattacharyya et al., 2007; Chen et al., 2002; Zhao et al., 2005), microglia (Zhou et al., 2007), T lymphocytes (Li et al., 2006), dermal, lung and synovial fibroblasts (Phillips et al., 2006; Toh et al., 2004; Yang et al., 2006), endothelial cells (Furst et al., 2007), osteoblasts (Engelbrecht et al., 2003; Leclerc et al., 2004), keratinocytes (Onda et al., 2006; Stojadinovic et al., 2006), adipocytes (Bazuine et al., 2004), lung epithelial cells (Chivers et al., 2006; Hermoso et al., 2004), airway smooth muscle cells (Issa et al., 2007) and HeLa cells (Imasato et al., 2002; Lasa et al., 2002). Typically expression is quite rapid (within one hour), sustained (up to 24 hours), requires relatively low concentrations of GC, and is blocked by the GR antagonist RU486. In transfected COS7 cells a murine DUSP1 promoter construct was activated by dex in a manner dependent on GR dimerization (Kassel et al., 2001). However, the induction of DUSP1 by dex was unimpaired in mouse macrophages expressing only GR^{dim} (Abraham et al., 2006), implying that GR dimerization is unnecessary. The precise mechanism of regulation of DUSP1 by GCs remains to be determined.

DUSP1 is otherwise known as MAPK phosphatase 1 (MKP-1) because it dephosphorylates and inactivates members of the mitogen-activated protein kinase (MAPK) family. Preferred targets are cJun N-terminal kinase (JNK) and p38 MAPK (Franklin and Kraft, 1997), although GC-induced expression of DUSP1 has also been linked to inhibition of the extracellular signal-regulated kinase (ERK) pathway in certain cell types (Kassel et al., 2001; Wu, Roth et al., 2006). The substrate selectivity of DUSP1 is not fully understood (Abraham and Clark, 2006). The MAPKs regulate inflammatory gene expression at both transcriptional and post-transcriptional levels via the phosphorylation of transcription factors and RNA binding proteins (Clark et al., 2003; Dean et al., 2004; Ip and Davis, 1998; Kracht and Saklatvala, 2002; Ono and Han, 2000). DUSP1 is induced by pro-inflammatory stimuli and forms a negative feedback loop to limit MAPK signaling and the expression of inflammatory mediators. Hence

overexpression of DUSP1 attenuates signaling of the JNK and p38 MAPK pathways and inhibits the expression of several inflammatory genes (Chen et al., 2002; Nimah et al., 2005; Zhao et al., 2005). Conversely, DUSP1^{-/-} macrophages show abnormally prolonged activation of JNK and p38, which results in overexpression of inflammatory genes (Chi et al., 2006; Hammer et al., 2006; Salojin et al., 2006; Zhao et al., 2006). In LPS-induced endotoxemia and collagen-induced arthritis (experimental models of acute or chronic inflammation, respectively), DUSP1^{-/-} mice show exaggerated responses (Chi et al., 2006; Hammer et al., 2006; Salojin et al., 2006; Zhao et al., 2006). Hence DUSP1 is an important negative regulator of inflammatory responses (Abraham and Clark, 2006; Dickinson and Keyse, 2006; Lang et al., 2006; Liu et al., 2007), and its induction by GCs is potentially a powerful anti-inflammatory mechanism (Clark, 2003; Clark and Lasa, 2003). Indeed, a variety of commonly prescribed GCs induced DUSP1 expression in alveolar macrophages in a manner roughly proportional to their anti-inflammatory efficacies (Zhao et al., 2005).

Macrophages derived from DUSP1^{-/-} mice displayed an interesting partial GC-insensitivity (Abraham et al., 2006) (Figure 1). Dex inhibited the expression of IL-1 α mRNA strongly in DUSP1^{+/+} but not at all in DUSP1^{-/-} macrophages. In contrast the expression of CSF2 mRNA was equally strongly inhibited by dex in both DUSP1^{+/+} and DUSP1^{-/-} macrophages. Between these extremes, many pro-inflammatory genes (for example COX-2, TNF and IL-1 β) showed intermediate responses, dex-mediated suppression being impaired to some extent but not ablated in the absence of DUSP1. From these observations it can be concluded that 1) the expression of DUSP1 contributes importantly to the anti-inflammatory action of GCs on murine macrophages; 2) at least one additional, DUSP1-independent mechanism exists for the inhibition of inflammatory gene expression; 3) individual genes appear to be suppressed by both DUSP1-dependent and DUSP1-independent mechanisms. In a simple model of an acute inflammatory response, GCs exerted anti-inflammatory effects in wild type but not DUSP1^{-/-} mice (Abraham et al.,

2006). Although these observations provide support for the hypothesis that DUSP1 is an important contributor to anti-inflammatory actions of GCs, several important questions remain unanswered.

LPS-induced lethal endotoxic shock in mice was dependent on p38 MAPK activation and could be inhibited by GCs (Bhattacharyya et al., 2007). Macrophage specific knockout of GR expression increased susceptibility to LPS-induced lethal endotoxic shock, which was associated with failure of GCs to induce DUSP1 and inhibit p38 MAPK activation (Bhattacharyya et al., 2007). This implies that the macrophage is an important site of action of GCs in one experimental model of acute inflammation, and that important anti-inflammatory effects are dependent on inhibition of p38 MAPK. Recent studies also implicate DUSP1 in the anti-inflammatory response to GCs in endothelial cells (Wadgaonkar et al., 2004; Furst et al., 2007), microglia (Zhou et al., 2007) and human airway smooth muscle cells (Issa et al., 2007). However, it is not known whether DUSP1 contributes to the anti-inflammatory effects of GCs on other cells such as mast cells, T lymphocytes or dendritic cells. Related to this, it will be important to establish whether ablation of the DUSP1 gene compromises the anti-inflammatory actions of GCs in complex models of immune-mediated inflammatory disease, and if so, in which cell types the expression of DUSP1 plays a critical role.

At least in macrophages DUSP1 was particularly important for GC-mediated suppression of inflammatory mRNAs that are stabilized by the p38 MAPK pathway (Abraham et al., 2006; Clark et al., 2003). Therefore dex may inhibit inflammatory gene expression in part by inducing DUSP1, inhibiting p38 MAPK and consequently destabilizing inflammatory mRNAs. However, this remains to be demonstrated, and other mechanisms may be involved. For example JNK is required for the phosphorylation and activation of c-Jun (Ip and Davis, 1998; Kracht and Saklatvala, 2002). GC-induced expression of DUSP1 is accompanied by a decrease in phosphorylation of nuclear c-Jun (Wu, Roth et al., 2006; Zhou et al., 2007), with consequences that may be indistinguishable from classical

transrepression of AP1. The p38 MAPK pathway can influence the transcriptional activation properties of NF κ B (Vermeulen et al., 2003) or its recruitment to binding sites in promoters of pro-inflammatory genes (Saccani et al., 2002). A bacterially encoded dual-specificity phosphatase that targets p38 MAPK inhibits the transcriptional activation of certain NF κ B-dependent promoters (Arbibe et al., 2007), and it is tempting to speculate that DUSP1 may have similar effects. The exact mechanisms by which GC-induced DUSP1 inhibits gene expression have not been elucidated.

In osteoblasts dex-induced expression of DUSP1 was associated with phosphatase-mediated inhibition of proliferation (Engelbrecht et al., 2003; Hulley et al., 2002). An involvement of DUSP1 in GC-induced osteoporosis has been postulated, but not yet proven. In adipocytes dex-induced DUSP1 expression was accompanied by impairment of insulin-induced glucose uptake (Bazuine et al., 2004), and DUSP1^{-/-} mice displayed alterations of fat metabolism, manifesting as increased resistance to diet-induced obesity (Wu, Roth et al., 2006). These findings imply that upregulation of DUSP1 by GCs may contribute to metabolic dysregulation. Another important side effect, GC-induced cataract, was suggested to involve the induction of DUSP1 expression in lens epithelial cells (Gupta et al., 2007). Upregulation of DUSP1 by GCs appears to contribute to resistance of breast cancer cells to chemotherapeutic agents (Wu et al., 2004; Wu et al., 2005; Wu, Zou et al., 2006). These observations raise the possibility that both anti-inflammatory and unwanted effects of GCs could be mediated by a single molecule, expressed in different tissues.

Tristetraprolin.

Tristetraprolin (TTP) is an mRNA destabilizing protein that recognizes specific transcripts and causes their rapid degradation via the recruitment of exonucleases (Carrick et al., 2004). A TTP knockout mouse strain has a complex phenotype with features of inflammatory arthritis, both of which are

A Clark Anti-inflammatory functions of glucocorticoid-induced genes Page 22 of 53

largely mediated by increased stability of TNF mRNA and increased expression of TNF protein (Carballo et al., 1998; Taylor et al., 1996). TTP recognizes the nonameric sequence UUAUUUAUU, present in the 3' untranslated region (UTR) of TNF mRNA (Brewer et al., 2004; Michel et al., 2003; Worthington et al., 2002). Many other mediators of immunity or inflammation are encoded by labile mRNAs that also have adenylate/uridylate-rich elements (AREs) in their 3' UTRs. COX-2, CSF2 and IL-2 genes are dysregulated in the absence of TTP (Carballo et al., 2000; Ogilvie et al., 2005; Phillips et al., 2004), and it seems likely that expression of other inflammatory mediators will also prove to be controlled by TTP. Inflammatory mRNAs can be stabilized via the phosphorylation and inactivation of TTP by MAPK-activated protein kinase 2, a kinase that is activated by p38 MAPK (Carballo et al., 2001; Chrestensen et al., 2004; Stoecklin et al., 2004). At least in cells of the myeloid lineage, this appears to be the principal mechanism for post-transcriptional regulation of inflammatory genes by the p38 MAPK pathway. Interestingly, DUSP1 mRNA contains two copies of the UUAUUUAUU sequence and DUSP1 expression is dependent on p38 MAPK in UV-stimulated HeLa cells (Lasa et al., 2002). However, our preliminary experiments suggest that p38 MAPK does not regulate DUSP1 expression at a post-transcriptional level, at least in HeLa cells (unpublished observations).

Expression of TTP mRNA was elevated by dex treatment of pulmonary epithelial A549 and BEAS-2B cells (Ishmael et al., 2007; Smoak and Cidlowski, 2006), primary human keratinocytes (Stojadinovic et al., 2006) or HeLa cells (our unpublished observations). GC-induced expression of TTP mRNA and protein in several rat tissues was confirmed by quantitative PCR and western blotting (Smoak and Cidlowski, 2006). siRNA-mediated reduction of TTP expression decreased the inhibitory effect of dex on expression of endogenous TNF mRNA or a reporter carrying the TNF 3' UTR (Smoak and Cidlowski, 2006). Importantly, inhibitory effects of GC (particularly on chemokine gene expression) were impaired in TTP^{-/-} fibroblasts (Ishmael et al., 2007).

The induction of TTP may contribute to the post-transcriptional inhibitory effects of GCs described above. However, it should be noted that dex inhibited the LPS-induced expression of TTP mRNA and protein in macrophages (Jalonen et al., 2005), and had no effect on PMA/PHA-induced TTP protein expression in human peripheral blood mononuclear cells (Bergmann et al., 2004). The control of TTP expression by pro-inflammatory stimuli and GCs needs further investigation. It will also be interesting to determine whether anti-inflammatory actions of GCs are impaired in TTP^{-/-} macrophages and other cells. There is potential for cooperative effects of two different GC-induced factors. GCs could induce the expression of TTP and at the same time increase its activity by upregulating DUSP1 and inhibiting p38 MAPK. As yet, this hypothesis remains unexplored.

Mast cell signaling effectors.

Activation of mast cells through engagement of Ig receptors initiates a complex cell signaling cascade that includes stimulation of src-like tyrosine kinases, activation of PI3K-Akt and Raf-MEK-ERK pathways, and mobilization of intracellular calcium stores. These coordinately regulate not only the upregulation of pro-inflammatory gene expression, but also the rapid release of preformed inflammatory mediators from storage granules. In allergic diseases like asthma GCs can inhibit both immediate and delayed responses to antigen exposure (Kassel and Cato, 2002). In response to dex, RBL-2H3 cells (a rat mast cell line) upregulated DUSP1 (Kassel et al., 2001) Dok-1 (downstream of tyrosine kinase 1) (Hiragun et al., 2005) and SLAP (src-like adaptor protein) (Hiragun et al., 2006). Each of these is an inhibitor of signaling pathways critical to mast cell activation. DUSP1 (see above) was implicated in dex-mediated inhibition of mast cell ERK signaling (Kassel et al., 2001). Dok-1 can associate with the Ras GTPase-activating protein and inhibit activation of Raf and ERK. Overexpression of Dok-1 partially mimicked effects of dex on the ERK pathway, whereas RNAi-mediated reduction of Dok-1 levels enhances inflammatory responses of mast cells (Hiragun et al., 2005). Overexpression of SLAP mimicked several effects of dex, inhibiting antigen-induced

phosphorylation of the src-like tyrosine kinase syk, activation of ERK, calcium mobilization and degranulation. Conversely, siRNA-mediated reduction of SLAP levels impaired the effects of dex on tyrosine kinase activation and calcium mobilization (Hiragun et al., 2006).

It is striking that mast cells respond to GCs by upregulating a number of negative regulators of signaling. These genomic responses to GCs are generally quite slow, and are probably most significant in the context of sustained GC exposure. There is not yet compelling evidence as to which negative regulators are important for the anti-inflammatory effects of GCs *in vivo*, since GC effects on mast cell function have not been described in DUSP1^{-/-}, Dok-1^{-/-} (Di Cristofano et al., 2001; Yamanashi et al., 2000) or SLAP^{-/-} (Sosinowski et al., 2000) mice. RNAi knockdown of SLAP reduced the effects of dex on signaling pathways but did not alter dex-mediated inhibition of mast cell degranulation (Hiragun et al., 2006). Possibly GC-induced inhibitors of signaling serve redundant functions in the inhibition of mast cell responses. It has not been reported whether GCs induce expression of Dok-1 or SLAP in cells other than mast cells.

Glucocorticoid Inducible Leucine Zipper.

GCs upregulate glucocorticoid inducible leucine zipper (GILZ) expression in T cells (Asselin-Labat et al., 2004; D'Adamio et al., 1997; Mittelstadt and Ashwell, 2001; Riccardi et al., 2001), mast cells (Godot et al., 2006), eosinophils (Arthaningtyas et al., 2005), epithelial (Bhalla et al., 2006; Chivers et al., 2006; Eddleston et al., 2007; Soundararajan et al., 2005; Wang et al., 2004), and myeloid cells (Berrebi et al., 2003; Cohen et al., 2006; Ehrchen et al., 2007). Relatively high basal GILZ expression has also been recorded in brain, lung and skeletal muscle (Cannarile et al., 2001). GILZ is a 137 amino acid protein with a central leucine zipper (LZ) dimerization domain. Unlike other LZ proteins it is not known to bind directly to DNA, but interacts with NFκB and impairs its transactivation function (Ayroldi et al., 2001; Berrebi et al., 2003; DiMarco et al., 2006; Eddleston et al., 2007; Riccardi et al.,

2001). GILZ may similarly inhibit the function of AP1 (Mittelstadt and Ashwell, 2001) and transcription factors that recognise the conserved lymphokine element 0 (CLE0), a cis-acting element required for efficient expression of IL-5 (Arthaningtyas et al., 2005). Overexpression of GILZ in transfected T cells downregulates IL-2 and Fas ligand, protecting against activation-induced cell death (Ayroldi et al., 2001; Ayroldi et al., 2002; D'Adamio et al., 1997). T cell-directed overexpression of GILZ in a transgenic mouse strain mimics some of the effects of GCs on the immune system, for example inhibition of activation-induced apoptosis (Delfino et al., 2006) and skewing of T cell differentiation towards the Th2 subtype (Cannarile et al., 2006). Therefore, some of the immune modulatory effects of GCs may be mediated in part by the expression of GILZ in T cells.

GILZ overexpression in a monocytic cell line can downregulate chemokines and activation markers (Berrebi et al., 2003), suggesting an anti-inflammatory function in the myeloid compartment. Immunomodulatory effects of GCs on dendritic cells were mimicked by the overexpression of GILZ and blocked by siRNA-mediated knockdown of GILZ (Cohen et al., 2006). RNA interference experiments also supported a role for GILZ in the inhibition of CXCL8 expression in endothelial cells (Eddleston et al., 2007). On the other hand, GILZ stimulated rather than suppressed the expression and activity of the epithelial sodium channel α (ENaC α) (Bhalla et al., 2006; Soundararajan et al., 2005), possibly via inhibition of the ERK pathway (Ayroldi et al., 2002; Soundararajan et al., 2005). ENaC α expression is thought to contribute to GC-induced hypertension (Fuller et al., 2000; Itani et al., 2002; Sayegh et al., 1999; Stokes and Sigmund, 1998). This raises the interesting possibility that a GC-induced gene could contribute to both anti-inflammatory and harmful effects in a single cell type. Unfortunately no knockout has so far been generated to provide conclusive proof of the suggested functions of GILZ in myeloid or other cells. In transfected cells the induction of GILZ by GC was dependent on dimerization of GR (Rogatsky et al., 2003), although GILZ expression in the GR^{dim}

mouse has not yet been described. GR interacted *in vivo* with a distal 5' region of the GILZ locus that contains four divergent GRE sequences (Wang et al., 2004). Both these GR binding sites and FoxO3 binding sites (Asselin-Labat et al., 2005) have been implicated in the transcriptional regulation of GILZ by GCs.

IL-10.

IL-10 is a pleiotropic anti-inflammatory and immunomodulatory cytokine, which is expressed by several haematopoietic cell types (Grutz, 2005; Williams et al., 2004). Induction of IL-10 expression has been suggested to contribute to the anti-inflammatory properties of GCs in rheumatoid arthritis (Verhoef et al., 1999), asthma (Karagiannidis et al., 2004; Stelmach et al., 2002), multiple sclerosis (Gayo et al., 1998) and cardiac bypass surgery (Tabardel et al., 1996). In these complex clinical settings the cellular source of IL-10 is often unclear. *In vitro*, purified monocytes or macrophages but not B or T cells expressed IL-10 in response to GC (Ehrchen et al., 2007; Hodge et al., 1999; Marchant et al., 1996; Mozo et al., 2004). Differentiation of dendritic cells (dc) in the presence of GC gave rise to a dc population with decreased cell surface costimulatory molecule expression and increased capacity to express IL-10 when stimulated (de Jong et al., 1999; Dong et al., 2003; Duperrier et al., 2005; Matyszak et al., 2000; Piemonti et al., 1999; Rea et al., 2000; Rozkova et al., 2006). Antigen presentation by dc in the absence of a strong costimulatory signal can drive expansion of T cells that themselves express IL-10 and have immunosuppressive “regulatory” properties (Dong et al., 2003). Hence both direct and indirect pathways for the induction of IL-10 expression may contribute to immunosuppressive effects of GCs.

The perfect palindromic sequence AGAACAGCTGTTCT in the human IL-10 promoter resembles a GRE, although with two rather than three nucleotides between the TGTCT half sites. This sequence is quite well conserved in the murine IL-10 promoter, but it is not yet known whether either element

A Clark Anti-inflammatory functions of glucocorticoid-induced genes Page 27 of 53

contributes to GC-mediated upregulation of IL-10. Expression of IL-10 is acutely dependent on p38 MAPK (Foey et al., 1998; Koprak et al., 1999; Ma et al., 2001) and dysregulated in DUSP1^{-/-} macrophages (Abraham et al., 2006; Chi et al., 2006; Hammer et al., 2006; Zhao et al., 2006). There may exist a pathway for GC-mediated downregulation of IL-10 expression via the induction of DUSP1 and inhibition of p38 MAPK, but this has not been conclusively demonstrated (Abraham et al., 2006). The regulation of IL-10 is not well understood, and may be determined by the outcome of both positive and negative GC-induced mechanisms and other signaling pathways.

Annexin A1.

Annexin A1 (AnxA1) is a member of a family of calcium-dependent phospholipid binding proteins that provide a functional link between calcium signalling and membrane organization (Gerke et al., 2005). Members of this family are postulated to play roles in the establishment or maintenance of membrane microdomains and communication between membrane compartments (Gerke et al., 2005). AnxA1 was first identified as a factor that was released from GC-stimulated cells *in vitro* or *in vivo*, and exerted anti-inflammatory effects mirroring those of GCs. Most notably it inhibited release of pro-inflammatory prostaglandins, and impaired leukocyte extravasation at sites of inflammation (Chatterjee et al., 2005; de Coupade et al., 2003; Gavins et al., 2003; Lim and Pervaiz, 2007; Liu et al., 2005; Parente and Solito, 2004). AnxA1 is relocalized from the cytoplasm to the plasma membrane in response to a variety of agonists including GCs, and can be externalized or secreted via an uncharacterized mechanism. The N-terminus of AnxA1, which is distinct from those of other annexins, is thought to exert anti-inflammatory effects by signalling through members of the formyl peptide receptor (FPR) family, in particular FPRL1 (Ernst et al., 2004; Gavins et al., 2003; Hayhoe et al., 2006; John et al., 2007; Perretti et al., 2001; Walther et al., 2000). This cell surface receptor also recognizes as a ligand lipoxin A₄, a prostanoid involved in the resolution of inflammation.

Neutralizing antibodies against AnxA1 impaired the anti-inflammatory effects of GCs on carageenin-induced paw oedema (Duncan et al., 1993), ischaemia-reperfusion injury (D'Amico et al., 2000) and adjuvant-induced arthritis (Yang et al., 1999). Inflammatory responses of an AnxA1 null mouse strain were exaggerated (Chatterjee et al., 2005; Hannon et al., 2003; Warne et al., 2006; Yang et al., 2004), and cells derived from these mice overexpressed COX-2, IL-1 β and -6 in response to pro-inflammatory stimuli (Croxtall et al., 2003; Damazo et al., 2006; Hannon et al., 2003; Yang et al., 2006; Yona et al., 2004; Yona et al., 2005), suggesting that AnxA1 is an endogenous inhibitor of inflammatory responses (Perretti and Gavins, 2003). It should be noted here that cells lacking AnxA1 also showed differences of morphology (Croxtall et al., 2003) and phagocytic properties (Yona et al., 2004), which might be indicative of altered membrane physiology. Importantly, suppressive effects of GCs on carageenin-induced oedema, zymosan-induced peritonitis and antigen-induced arthritis were impaired in AnxA1^{-/-} mice (Hannon et al., 2003; Yang et al., 2004). GCs failed to inhibit the expression of IL-6 and COX-2 in lung fibroblasts lacking AnxA1 (Hannon et al., 2003; Yang et al., 2006). In part this may be explained by the failure of AnxA1^{-/-} cells to express DUSP1 and inhibit p38 MAPK signalling (Yang et al., 2006).

From these observations it has been argued that AnxA1 is a mediator of certain anti-inflammatory actions of GCs. It also appears to contribute to at least one of the important side effects of GCs, the suppression of the HPA axis and consequent adrenal insufficiency (Buckingham et al., 2006). To clarify whether externalization of AnxA1 is crucial to its role in GC responses, it would be of interest to determine whether anti-inflammatory actions of GCs are impaired in FPRL1 null mice. Although AnxA1 mRNA expression is upregulated by GCs this response tends to be quite slow and modest (less than two-fold) (Solito et al., 2003). It may have more to do with the homeostatic maintenance of cellular AnxA1 levels than the rapid anti-inflammatory response to GCs.

IL-1 receptor type II.

The non-signaling type II IL-1 receptor (IL-1RII) is thought to function as a decoy receptor that inhibits cellular responses to IL-1 (Neumann et al., 2000). GC-induced upregulation of IL-1RII has been described in a number of studies (Brown et al., 1996; Colotta et al., 1993; Ehrchen et al., 2007; Pousset et al., 2001) and may contribute to inhibition of a very specific subset of (IL-1-mediated) inflammatory responses. This decoy receptor upregulation must be seen in the context of GC-induced upregulation of several signaling receptors, such as Toll-like receptors, that can potentially transmit pro-inflammatory signals (Rozkova et al., 2006; Schleimer, 2004).

 β adrenergic agonist receptors.

β adrenergic agonists cooperate with GCs to exert anti-inflammatory effects in asthma (Barnes, 2002; Hancox, 2006). GCs can upregulate expression of β 1 and β 2 adrenergic receptors (Collins et al., 1988; Mak et al., 1995; Tseng et al., 2001), potentially providing a rather indirect anti-inflammatory mechanism by sensitizing target cells to additional anti-inflammatory stimuli.

CONCLUSIONS.

The side effects of GCs involve changes in expression of countless genes in several different tissues. Although the underlying molecular mechanisms are “complex, distinct, and frequently only partly understood” (Schacke et al., 2002), there is a growing recognition that both activation and inhibition of gene expression by GR are involved. We would argue that exactly the same is true of the anti-inflammatory effects of GCs (see Figure 2). As discussed above, GCs can exert anti-inflammatory effects at both transcriptional and post-transcriptional levels, via both transrepression and transcriptional activation. The GC-induced expression of DUSP1, GILZ, Dok-1 or SLAP can interfere with signaling pathways that are activated by pro-inflammatory stimuli, and hence block pro-

inflammatory gene expression. The function of NF κ B may be inhibited via the upregulation of I κ B α , GILZ and perhaps DUSP1, with consequences that are difficult to distinguish from classical transrepression without careful case-by-case analysis. In a similar fashion, DUSP1 expression and JNK suppression may contribute to GC-mediated inhibition of AP1 function. Induction of DUSP1 and TTP gene expression contributes to anti-inflammatory effects of GCs at the post-transcriptional level. This is emerging as an important component of the anti-inflammatory armoury of GCs, but is absent from models based on transrepression, which view changes in mRNA abundance as equivalent to changes at the transcriptional level. Secreted or externalized proteins such as IL-10, AnxA1 and IL-1RII are also likely to contribute to the anti-inflammatory response to GCs. Other GC-induced anti-inflammatory mediators have been omitted from this review for reasons of space, and it is probable that yet more will come to light. It is difficult to argue that a single GC-induced factor plays an indispensable role in the anti-inflammatory response, but still harder to argue that the positive regulation of gene expression by GCs is irrelevant to their anti-inflammatory action.

In fact the side effects of GCs can be regarded as physiological responses that have evolved through natural selection but are driven to extremes by abnormally sustained high concentrations of potent, synthetic GCs in the bloodstream. For example the induction of gluconeogenesis is, on one hand, a component of the healthy response to physical or psychological stress and, on the other, an underlying cause of GC-induced diabetes mellitus. The distinction between anti-inflammatory effects and side effects seems rather artificial in the sense that both are “on-target” GC responses. Given the extraordinary array of mechanisms through which GCs can modulate gene expression, why should we expect distinct mechanisms to be deployed along the lines of clinical convenience or inconvenience? It is difficult to provide an account of evolutionary pressures that would lead to such an outcome.

A problem with the current paradigm is that many rather simple phenomena have been made to stand as representative of biological processes that are vastly more complex. Reporter constructs containing multimerized, idealized palindromic GREs are considered to represent GC-induced gene expression, although it now seems clear that straightforward GRE-mediated transcriptional regulation accounts for a small fraction of the GC response. Alternatively, model genes such as TAT and PEPCK are used as illustrations of GC-induced transcriptional responses. These genes are regulated by GCs in a more complex manner than originally believed, but other GC targets are controlled by dissimilar, equally complex and extremely varied mechanisms. Again, induction of TAT and PEPCK is considered representative of GC-induced side effects, although such side effects are poorly understood and highly diverse in mechanism. The argument that GC-induced gene expression does not contribute to the anti-inflammatory response is largely based on the failure of GR^{dim} to induce TAT and PEPCK, yet these genes are not putative anti-inflammatory mediators. As surrogate markers for cellular responses to GCs, TAT and PEPCK are employed far beyond their utility. Furthermore, models that do not adequately reflect the complexity of GC action are likely to have poor predictive power. Simple drug screens based on idealized reporter constructs or a few representative GC targets seem unlikely to succeed in identifying compounds that clearly discriminate between the positive and negative regulatory properties of GR. For example a first generation “dissociated” GC failed to activate a GRE-dependent reporter construct but strongly induced expression of at least three putative anti-inflammatory mediators, AnxA1, GILZ and DUSP1 (Chivers et al., 2006; Janka-Junttila et al., 2006).

There is a strong case for developing a more comprehensive model of anti-inflammatory actions of GCs, in which the importance of GC-induced gene expression is recognized and both transcriptional and post-transcriptional mechanisms are featured. The relative importance of transcriptional and post-transcriptional effects on a given gene may be dependent on the cellular context, activation status and time at which GCs are present. As illustrated schematically in Figure 2, the molecular mechanisms

involved in the side-effects and anti-inflammatory actions of GCs may prove to be inextricably tangled. An important new concern is that upregulated factors may prove to contribute to both anti-inflammatory and unwanted effects of GCs. DUSP1 is a putative example of such a two-edged mediator of GC responses (represented by gene B in Figure 2B). What would all of this imply for the development of safer anti-inflammatory therapies? As argued elsewhere (Hiragun et al., 2006; Smoak and Cidlowski, 2006), novel GR agonists that fail to activate gene expression may lack an important component of anti-inflammatory action. On the other hand, attempts to exert anti-inflammatory effects by modulating expression of DUSP1 or other factors risks causing side effects unless exquisite tissue targeting and control can be achieved. In summary, there are unlikely to be effective short-cuts to the discovery of truly dissociated GR agonists and it is debatable whether such compounds, if they can be identified, will yield the predicted clinical benefits.

Acknowledgements.

The work of Andy Clark's lab is supported by a programme grant from the Medical Research Council (UK). The author is grateful to Sonya Abraham, Rob Newton, Jeremy Saklatvala and Cristiana Stellato for helpful discussions during the writing of this review.

Accepted Manuscript

REFERENCES.

- Abraham, S. M., Clark, A. R., 2006. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. *Biochem. Soc. Trans.* 34, 1018-1023.
- Abraham, S. M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann, J., Saklatvala, J., Clark, A. R., 2006. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. *J. Exp. Med.* 203, 1883-1889.
- Adcock, I. M., Nasuhara, Y., Stevens, D. A., Barnes, P. J., 1999. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. *Br. J. Pharmacol.* 127, 1003-1011.
- Adcock, I. M., Newton, R., Barnes, P. J., 1997. NF-kappa B involvement in IL-1 beta-induction of GM-CSF and COX-2: inhibition by glucocorticoids does not require I-kappa B. *Biochem. Soc. Trans.* 25, 154S.
- Aeberli, D., Yang, Y., Mansell, A., Santos, L., Leech, M., Morand, E. F., 2006. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. *FEBS Lett.* 580, 974-981.
- Aittomaki, S., Pesu, M., Groner, B., Janne, O. A., Palvimo, J. J., Silvennoinen, O., 2000. Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc gamma receptor I in monocytes. *J. Immunol.* 164, 5689-5697.
- Alam, T., An, M. R., Mifflin, R. C., Hsieh, C. C., Ge, X., Papaconstantinou, J., 1993. trans-activation of the alpha 1-acid glycoprotein gene acute phase responsive element by multiple isoforms of C/EBP and glucocorticoid receptor. *J. Biol. Chem.* 268, 15681-15688.
- Almon, R. R., Dubois, D. C., Jin, J. Y., Jusko, W. J., 2005. Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. *Aaps J.* 7, E156-194.
- Amano, Y., Lee, S. W., Allison, A. C., 1993. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. *Mol. Pharmacol.* 43, 176-182.
- Arbibe, L., Kim, D. W., Batsche, E., Pedron, T., Mateescu, B., Muchardt, C., Parsot, C., Sansonetti, P. J., 2007. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. *Nat. Immunol.* 8, 47-56.
- Arizmendi, C., Liu, S., Croniger, C., Poli, V., Friedman, J. E., 1999. The transcription factor CCAAT/enhancer-binding protein beta regulates gluconeogenesis and phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. *J. Biol. Chem.* 274, 13033-13040.
- Arthaningtyas, E., Kok, C. C., Mordvinov, V. A., Sanderson, C. J., 2005. The conserved lymphokine element 0 is a powerful activator and target for corticosteroid inhibition in human interleukin-5 transcription. *Growth Factors* 23, 211-221.
- Asselin-Labat, M. L., Biola-Vidamment, A., Kerbrat, S., Lombes, M., Bertoglio, J., Pallardy, M., 2005. FoxO3 mediates antagonistic effects of glucocorticoids and interleukin-2 on glucocorticoid-induced leucine zipper expression. *Mol. Endocrinol.* 19, 1752-1764.
- Asselin-Labat, M. L., David, M., Biola-Vidamment, A., Lecoeuche, D., Zennaro, M. C., Bertoglio, J., Pallardy, M., 2004. GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin-2 withdrawal-induced apoptosis. *Blood* 104, 215-223.
- Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., Karin, M., 1995. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. *Science* 270, 286-290.
- Aurrekoetxea-Hernandez, K., Buetti, E., 2004. Transforming growth factor beta enhances the glucocorticoid response of the mouse mammary tumor virus promoter through Smad and GA-binding proteins. *J. Virol.* 78, 2201-2211.

- Auwardt, R. B., Mudge, S. J., Chen, C. G., Power, D. A., 1998. Regulation of nuclear factor kappaB by corticosteroids in rat mesangial cells. *J. Am. Soc. Nephrol.* 9, 1620-1628.
- Ayrolidi, E., Migliorati, G., Bruscoli, S., Marchetti, C., Zollo, O., Cannarile, L., D'Adamio, F., Riccardi, C., 2001. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. *Blood* 98, 743-753.
- Ayrolidi, E., Zollo, O., Macchiarulo, A., Di Marco, B., Marchetti, C., Riccardi, C., 2002. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. *Mol. Cell. Biol.* 22, 7929-7941.
- Barnes, P. J., 2002. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. *Eur. Respir. J.* 19, 182-191.
- Bazuine, M., Carlotti, F., Tafrechi, R. S., Hoebe, R. C., Maassen, J. A., 2004. Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. *Mol. Endocrinol.* 18, 1697-1707.
- Beg, A. A., Sha, W. C., Bronson, R. T., Baltimore, D., 1995. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. *Genes Dev.* 9, 2736-2746.
- Belvisi, M. G., Brown, T. J., Wicks, S., Foster, M. L., 2001. New Glucocorticosteroids with an improved therapeutic ratio? *Pulm. Pharmacol. Ther.* 14, 221-227.
- Berg, T., Didon, L., Barton, J., Andersson, O., Nord, M., 2005. Glucocorticoids increase C/EBPbeta activity in the lung epithelium via phosphorylation. *Biochem. Biophys. Res. Commun.* 334, 638-645.
- Bergmann, M. W., Staples, K. J., Smith, S. J., Barnes, P. J., Newton, R., 2004. Glucocorticoid inhibition of granulocyte macrophage-colony-stimulating factor from T cells is independent of control by nuclear factor-kappaB and conserved lymphokine element 0. *Am. J. Respir. Cell Mol. Biol.* 30, 555-563.
- Berkman, N., Jose, P. J., Williams, T. J., Schall, T. J., Barnes, P. J., Chung, K. F., 1995. Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages. *Am. J. Physiol.* 269, L443-452.
- Berrebi, D., Bruscoli, S., Cohen, N., Foussat, A., Migliorati, G., Bouchet-Delbos, L., Maillot, M. C., Portier, A., Couderc, J., Galanaud, P., et al., 2003. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. *Blood* 101, 729-738.
- Bhalla, V., Soundararajan, R., Pao, A. C., Li, H., Pearce, D., 2006. Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ. *Am. J. Physiol. Renal Physiol.* 291, F714-721.
- Bhattacharyya, S., Brown, D. E., Brewer, J. A., Vogt, S. K., Muglia, L. J., 2007. Macrophage glucocorticoid receptors regulate Toll-like receptor-4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. *Blood*.
- Bladh, L. G., Liden, J., Dahlman-Wright, K., Reimers, M., Nilsson, S., Okret, S., 2005. Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. *Mol. Pharmacol.* 67, 815-826.
- Boruk, M., Savory, J. G., Hache, R. J., 1998. AF-2-dependent potentiation of CCAAT enhancer binding protein beta-mediated transcriptional activation by glucocorticoid receptor. *Mol. Endocrinol.* 12, 1749-1763.
- Brach, M. A., Gruss, H. J., Riedel, D., Asano, Y., De Vos, S., Herrmann, F., 1992. Effect of antiinflammatory agents on synthesis of MCP-1/JE transcripts by human blood monocytes. *Mol. Pharmacol.* 42, 63-68.

- Brewer, B. Y., Malicka, J., Blackshear, P. J., Wilson, G. M., 2004. RNA sequence elements required for high affinity binding by the zinc finger domain of tristetraprolin: conformational changes coupled to the bipartite nature of Au-rich mRNA-destabilizing motifs. *J. Biol. Chem.* 279, 27870-27877.
- Brierley, M. M., Fish, E. N., 2005. Stats: multifaceted regulators of transcription. *J. Interferon Cytokine Res.* 25, 733-744.
- Brostjan, C., Anrather, J., Csizmadia, V., Stroka, D., Soares, M., Bach, F. H., Winkler, H., 1996. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. *J. Biol. Chem.* 271, 19612-19616.
- Brown, E. A., Dare, H. A., Marsh, C. B., Wewers, M. D., 1996. The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1r II) in monocytes: a comparison to interleukin 1 beta (IL-1 beta) and interleukin 1 receptor antagonist (IL-1ra). *Cytokine* 8, 828-836.
- Buckingham, J. C., John, C. D., Solito, E., Tierney, T., Flower, R. J., Christian, H., Morris, J., 2006. Annexin 1, glucocorticoids, and the neuroendocrine-immune interface. *Ann. N. Y. Acad. Sci.* 1088, 396-409.
- Cannarile, L., Fallarino, F., Agostini, M., Cuzzocrea, S., Mazzon, E., Vacca, C., Genovese, T., Migliorati, G., Ayroldi, E., Riccardi, C., 2006. Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. *Blood* 107, 1039-1047.
- Cannarile, L., Zollo, O., D'Adamio, F., Ayroldi, E., Marchetti, C., Tabilio, A., Bruscoli, S., Riccardi, C., 2001. Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene. *Cell Death Differ.* 8, 201-203.
- Carballo, E., Cao, H., Lai, W. S., Kennington, E. A., Campbell, D., Blackshear, P. J., 2001. Decreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway. *J. Biol. Chem.* 276, 42580-42587.
- Carballo, E., Lai, W. S., Blackshear, P. J., 1998. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. *Science* 281, 1001-1005.
- Carballo, E., Lai, W. S., Blackshear, P. J., 2000. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. *Blood* 95, 1891-1899.
- Carrick, D. M., Lai, W. S., Blackshear, P. J., 2004. The tandem CCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. *Arthritis Res. Ther.* 6, 248-264.
- Cassuto, H., Kochan, K., Chakravarty, K., Cohen, H., Blum, B., Olswang, Y., Hakimi, P., Xu, C., Massillon, D., Hanson, R. W., et al., 2005. Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit. *J. Biol. Chem.* 280, 33873-33884.
- Cha, H. H., Cram, E. J., Wang, E. C., Huang, A. J., Kasler, H. G., Firestone, G. L., 1998. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells. *J. Biol. Chem.* 273, 1998-2007.
- Chang, C. J., Chen, Y. L., Lee, S. C., 1998. Coactivator TIF1beta interacts with transcription factor C/EBPbeta and glucocorticoid receptor to induce alpha1-acid glycoprotein gene expression. *Mol. Cell. Biol.* 18, 5880-5887.
- Chang, M. M., Juarez, M., Hyde, D. M., Wu, R., 2001. Mechanism of dexamethasone-mediated interleukin-8 gene suppression in cultured airway epithelial cells. *Am. J. Physiol. Lung Cell Mol. Physiol.* 280, L107-115.

- Chatterjee, B. E., Yona, S., Rosignoli, G., Young, R. E., Nourshargh, S., Flower, R. J., Perretti, M., 2005. Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. *J. Leukoc. Biol.* 78, 639-646.
- Chaudhary, L. R., Avioli, L. V., 1996. Regulation of interleukin-8 gene expression by interleukin-1beta, osteotropic hormones, and protein kinase inhibitors in normal human bone marrow stromal cells. *J. Biol. Chem.* 271, 16591-16596.
- Chen, C. L., Yull, F. E., Cardwell, N., Singh, N., Strayhorn, W. D., Nanney, L. B., Kerr, L. D., 2000. RAG2^{-/-}, I kappa B-alpha^{-/-} chimeras display a psoriasiform skin disease. *J. Invest. Dermatol.* 115, 1124-1133.
- Chen, L., Finnerty, C., Gustafson, W. C., Bush, C. R., Chi, P., Guo, H., Luxon, B., Fields, A. P., Thompson, E. A., 2003. Genomic analysis of glucocorticoid-regulated promoters in murine T-lymphoma cells. *Recent Prog. Horm. Res.* 58, 155-174.
- Chen, P., Li, J., Barnes, J., Kokkonen, G. C., Lee, J. C., Liu, Y., 2002. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. *J. Immunol.* 169, 6408-6416.
- Chi, H., Barry, S. P., Roth, R. J., Wu, J. J., Jones, E. A., Bennett, A. M., Flavell, R. A., 2006. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. *Proc. Natl. Acad. Sci. U. S. A.* 103, 2274-2279.
- Chivers, J. E., Gong, W., King, E. M., Seybold, J., Mak, J. C., Donnelly, L. E., Holden, N. S., Newton, R., 2006. Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. *Mol. Pharmacol.* 70, 2084-2095.
- Chrestensen, C. A., Schroeder, M. J., Shabanowitz, J., Hunt, D. F., Pelo, J. W., Worthington, M. T., Sturgill, T. W., 2004. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. *J. Biol. Chem.* 279, 10176-10184.
- Clark, A. R., 2003. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? *J. Endocrinol.* 178, 5-12.
- Clark, A. R., Dean, J. L., Saklatvala, J., 2003. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. *FEBS Lett.* 546, 37-44.
- Clark, A. R., Lasa, M., 2003. Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways. *Curr. Opin. Pharmacol.* 3, 404-411.
- Cohen, N., Mouly, E., Hamdi, H., Maillot, M. C., Pallardy, M., Godot, V., Capel, F., Balian, A., Naveau, S., Galanaud, P., et al., 2006. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. *Blood* 107, 2037-2044.
- Collins, S., Caron, M. G., Lefkowitz, R. J., 1988. Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. *J. Biol. Chem.* 263, 9067-9070.
- Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J. G., Dower, S. K., Sims, J. E., Mantovani, A., 1993. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. *Science* 261, 472-475.
- Cram, E. J., Ramos, R. A., Wang, E. C., Cha, H. H., Nishio, Y., Firestone, G. L., 1998. Role of the CCAAT/enhancer binding protein-alpha transcription factor in the glucocorticoid stimulation of p21waf1/cip1 gene promoter activity in growth-arrested rat hepatoma cells. *J. Biol. Chem.* 273, 2008-2014.
- Crosson, S. M., Roesler, W. J., 2000. Hormonal regulation of the phosphoenolpyruvate carboxykinase gene. Role of specific CCAAT/enhancer-binding protein isoforms. *J. Biol. Chem.* 275, 5804-5809.
- Croxtall, J. D., Gilroy, D. W., Solito, E., Choudhury, Q., Ward, B. J., Buckingham, J. C., Flower, R. J., 2003. Attenuation of glucocorticoid functions in an Anx-A1^{-/-} cell line. *Biochem. J.* 371, 927-935.

- D'Adamio, F., Zollo, O., Moraca, R., Ayroldi, E., Bruscoli, S., Bartoli, A., Cannarile, L., Migliorati, G., Riccardi, C., 1997. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. *Immunity* 7, 803-812.
- Dahlman-Wright, K., Grandien, K., Nilsson, S., Gustafsson, J. A., Carlstedt-Duke, J., 1993. Protein-protein interactions between the DNA-binding domains of nuclear receptors: influence on DNA-binding. *J. Steroid Biochem. Mol. Biol.* 45, 239-250.
- Dahlman-Wright, K., Wright, A., Gustafsson, J. A., Carlstedt-Duke, J., 1991. Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids. *J. Biol. Chem.* 266, 3107-3112.
- Damazo, A. S., Yona, S., Flower, R. J., Perretti, M., Oliani, S. M., 2006. Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. *J. Immunol.* 176, 4410-4418.
- D'Amico, M., Di Filippo, C., La, M., Solito, E., McLean, P. G., Flower, R. J., Oliani, S. M., Perretti, M., 2000. Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. *FASEB J.* 14, 1867-1869.
- De Bosscher, K., Schmitz, M. L., Vanden Berghe, W., Plaisance, S., Fiers, W., Haegeman, G., 1997. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. *Proc. Natl. Acad. Sci. U. S. A.* 94, 13504-13509.
- De Bosscher, K., Vanden Berghe, W., Beck, I. M., Van Molle, W., Hennuyer, N., Hapgood, J., Libert, C., Staels, B., Louw, A., Haegeman, G., 2005. A fully dissociated compound of plant origin for inflammatory gene repression. *Proc. Natl. Acad. Sci. U. S. A.* 102, 15827-15832.
- de Coupade, C., Solito, E., Levine, J. D., 2003. Dexamethasone enhances interaction of endogenous annexin 1 with L-selectin and triggers shedding of L-selectin in the monocytic cell line U-937. *Br. J. Pharmacol.* 140, 133-145.
- de Jong, E. C., Vieira, P. L., Kalinski, P., Kapsenberg, M. L., 1999. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. *J. Leukoc. Biol.* 66, 201-204.
- De Miguel, F., Lee, S. O., Onate, S. A., Gao, A. C., 2003. Stat3 enhances transactivation of steroid hormone receptors. *Nucl. Recept.* 1, 3.
- Dean, J. L., Sully, G., Clark, A. R., Saklatvala, J., 2004. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. *Cell Signal* 16, 1113-1121.
- Delfino, D. V., Agostini, M., Spinicelli, S., Vacca, C., Riccardi, C., 2006. Inhibited cell death, NF-kappaB activity and increased IL-10 in TCR-triggered thymocytes of transgenic mice overexpressing the glucocorticoid-induced protein GILZ. *Int. Immunopharmacol.* 6, 1126-1134.
- Deroo, B. J., Archer, T. K., 2001. Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. *Mol. Biol. Cell* 12, 3365-3374.
- Dhawan, L., Liu, B., Blaxall, B. C., Taubman, M. B., 2007. A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein -1 mRNA stability. *J. Biol. Chem.* in press.
- Di Cristofano, A., Niki, M., Zhao, M., Karnell, F. G., Clarkson, B., Pear, W. S., Van Aelst, L., Pandolfi, P. P., 2001. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). *J. Exp. Med.* 194, 275-284.
- Diamond, M. I., Miner, J. N., Yoshinaga, S. K., Yamamoto, K. R., 1990. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. *Science* 249, 1266-1272.
- Dickinson, R. J., Keyse, S. M., 2006. Diverse physiological functions for dual-specificity MAP kinase phosphatases. *J. Cell Sci.* 119, 4607-4615.

- DiMarco, B. D., Massetti, M., Bruscoli, S., Macchiarulo, A., Virgilio, R. D., Velardi, E., Donato, V., Migliorati, G., Riccardi, C., 2006. Glucocorticoid-induced leucine zipper (GILZ)/NF- κ B interaction: role of GILZ homo-dimerization and C-terminal domain. *Nucleic Acids Res.*
- Dong, X., Bachman, L. A., Kumar, R., Griffin, M. D., 2003. Generation of antigen-specific, interleukin-10-producing T-cells using dendritic cell stimulation and steroid hormone conditioning. *Transpl. Immunol.* 11, 323-333.
- Doyle, S. L., O'Neill, L. A., 2006. Toll-like receptors: from the discovery of NF κ B to new insights into transcriptional regulations in innate immunity. *Biochem. Pharmacol.* 72, 1102-1113.
- Duncan, G. S., Peers, S. H., Carey, F., Forder, R., Flower, R. J., 1993. The local anti-inflammatory action of dexamethasone in the rat carrageenin oedema model is reversed by an antiserum to lipocortin 1. *Br. J. Pharmacol.* 108, 62-65.
- Duperrier, K., Velten, F. W., Bohlender, J., Demory, A., Metharom, P., Goerdts, S., 2005. Immunosuppressive agents mediate reduced allostimulatory properties of myeloid-derived dendritic cells despite induction of divergent molecular phenotypes. *Mol. Immunol.* 42, 1531-1540.
- Eberhardt, W., Schulze, M., Engels, C., Klasmeier, E., Pfeilschifter, J., 2002. Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor- κ B and Ets transcription factors. *Mol. Endocrinol.* 16, 1752-1766.
- Eddleston, J., Herschbach, J., Wagelie-Steffen, A. L., Christiansen, S. C., Zuraw, B. L., 2007. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. *J. Allergy Clin. Immunol.* 119, 115-122.
- Edwards, M. R., Mukaida, N., Johnson, M., Johnston, S. L., 2005. IL-1 β induces IL-8 in bronchial cells via NF- κ B and NF-IL6 transcription factors and can be suppressed by glucocorticoids. *Pulm. Pharmacol. Ther.* 18, 337-345.
- Ehrchen, J., Steinmuller, L., Barczyk, K., Tenbrock, K., Nacken, W., Eisenacher, M., Nordhues, U., Sorg, C., Sunderkotter, C., Roth, J., 2007. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. *Blood* 109, 1265-1274.
- Engelbrecht, Y., de Wet, H., Horsch, K., Langeveldt, C. R., Hough, F. S., Hulley, P. A., 2003. Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. *Endocrinology* 144, 412-422.
- Ernst, S., Lange, C., Wilbers, A., Goebeler, V., Gerke, V., Rescher, U., 2004. An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family. *J. Immunol.* 172, 7669-7676.
- Fan, J., Curry, S.L., Atasoy, U.X., Becker, K. G., Gorospe, M., Stellato, C., 2006. Genome-scale analysis of posttranscriptional effects of glucocorticoids (GC). *J. Allergy Clin. Immunol.* 117, S92.
- Fenger-Gron, M., Fillman, C., Norrild, B., Lykke-Andersen, J., 2005. Multiple processing body factors and the ARE binding protein TTP activate mRNA decapping. *Mol. Cell* 20, 905-915.
- Foey, A. D., Parry, S. L., Williams, L. M., Feldmann, M., Foxwell, B. M., Brennan, F. M., 1998. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF- α : role of the p38 and p42/44 mitogen-activated protein kinases. *J. Immunol.* 160, 920-928.
- Franklin, C. C., Kraft, A. S., 1997. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. *J. Biol. Chem.* 272, 16917-16923.
- Fuller, P. J., Brennan, F. E., Burgess, J. S., 2000. Acute differential regulation by corticosteroids of epithelial sodium channel subunit and Nedd4 mRNA levels in the distal colon. *Pflugers Arch.* 441, 94-101.

- Furst, R., Schroeder, T., Eilken, H. M., Bubik, M. F., Kierner, A. K., Zahler, S., Vollmar, A. M., 2007. MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium. *FASEB J.* 21, 74-80.
- Furuyama, T., Kitayama, K., Yamashita, H., Mori, N., 2003. Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. *Biochem. J.* 375, 365-371.
- Garside, H., Stevens, A., Farrow, S., Normand, C., Houle, B., Berry, A., Maschera, B., Ray, D., 2004. Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. *J. Biol. Chem.* 279, 50050-50059.
- Gavins, F. N., Yona, S., Kamal, A. M., Flower, R. J., Perretti, M., 2003. Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. *Blood* 101, 4140-4147.
- Gayo, A., Mozo, L., Suarez, A., Tunon, A., Lahoz, C., Gutierrez, C., 1998. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. *J. Neuroimmunol.* 85, 122-130.
- Gerke, V., Creutz, C. E., Moss, S. E., 2005. Annexins: linking Ca²⁺ signalling to membrane dynamics. *Nat. Rev. Mol. Cell. Biol.* 6, 449-461.
- Gille, J., Reisinger, K., Westphal-Varghese, B., Kaufmann, R., 2001. Decreased mRNA stability as a mechanism of glucocorticoid-mediated inhibition of vascular endothelial growth factor gene expression by cultured keratinocytes. *J. Invest. Dermatol.* 117, 1581-1587.
- Godot, V., Garcia, G., Capel, F., Arock, M., Durand-Gasselin, I., Asselin-Labat, M. L., Emilie, D., Humbert, M., 2006. Dexamethasone and IL-10 stimulate glucocorticoid-induced leucine zipper synthesis by human mast cells. *Allergy* 61, 886-890.
- Goppelt-Strube, M., Rehm, M., Schaefer, H. J., 2000. Induction of cyclooxygenase-2 by platelet-derived growth factor (PDGF) and its inhibition by dexamethasone are independent of NF-kappaB/IkappaB transcription factors. *Naunyn Schmiedeberg's Arch. Pharmacol.* 361, 636-645.
- Gotoh, T., Chowdhury, S., Takiguchi, M., Mori, M., 1997. The glucocorticoid-responsive gene cascade. Activation of the rat arginase gene through induction of C/EBPbeta. *J. Biol. Chem.* 272, 3694-3698.
- Grange, T., Cappabianca, L., Flavin, M., Sassi, H., Thomassin, H., 2001. In vivo analysis of the model tyrosine aminotransferase gene reveals multiple sequential steps in glucocorticoid receptor action. *Oncogene* 20, 3028-3038.
- Grange, T., Roux, J., Rigaud, G., Pictet, R., 1989. Two remote glucocorticoid responsive units interact cooperatively to promote glucocorticoid induction of rat tyrosine aminotransferase gene expression. *Nucleic Acids Res.* 17, 8695-8709.
- Grivennikov, S. I., Kuprash, D. V., Liu, Z. G., Nedospasov, S. A., 2006. Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: From simple paradigms to complex mechanisms. *Int. Rev. Cytol.* 252, 129-161.
- Grutz, G., 2005. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. *J. Leukoc. Biol.* 77, 3-15.
- Guhaniyogi, J., Brewer, G., 2001. Regulation of mRNA stability in mammalian cells. *Gene* 265, 11-23.
- Guido, E. C., Delorme, E. O., Clemm, D. L., Stein, R. B., Rosen, J., Miner, J. N., 1996. Determinants of promoter-specific activity by glucocorticoid receptor. *Mol. Endocrinol.* 10, 1178-1190.
- Gupta, V., Awasthi, N., Wagner, B. J., 2007. Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells. *Invest. Ophthalmol. Vis. Sci.* 48, 1724-1734.
- Hammer, M., Mages, J., Dietrich, H., Servatius, A., Howells, N., Cato, A. C., Lang, R., 2006. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. *J. Exp. Med.* 203, 15-20.

- Han, J., Thompson, P., Beutler, B., 1990. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. *J. Exp. Med.* 172, 391-394.
- Hancox, R. J., 2006. Interactions between corticosteroids and beta2-agonists. *Clin. Rev. Allergy Immunol.* 31, 231-246.
- Hannon, R., Croxtall, J. D., Getting, S. J., Roviezzo, F., Yona, S., Paul-Clark, M. J., Gavins, F. N., Perretti, M., Morris, J. F., Buckingham, J. C., et al., 2003. Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. *FASEB J.* 17, 253-255.
- Hayhoe, R. P., Kamal, A. M., Solito, E., Flower, R. J., Cooper, D., Perretti, M., 2006. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. *Blood* 107, 2123-2130.
- Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., Cato, A. C., 1997. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. *EMBO J.* 16, 4698-4707.
- Heck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H. J., Herrlich, P., Cato, A. C., 1994. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. *EMBO J.* 13, 4087-4095.
- Hench, P.S., 1950. The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotrophic hormone. http://nobelprize.org/nobel_prizes/medicine/laureates/1950/hench-lecture.pdf.
- Henderson, B. R., Kefford, R. F., 1993. Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells. *Br. J. Cancer* 67, 99-101.
- Hermoso, M. A., Matsuguchi, T., Smoak, K., Cidrowski, J. A., 2004. Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expression. *Mol. Cell. Biol.* 24, 4743-4756.
- Hernandez, R., Teruel, T., Lorenzo, M., 2003. Insulin and dexamethasone induce GLUT4 gene expression in foetal brown adipocytes: synergistic effect through CCAAT/enhancer-binding protein alpha. *Biochem. J.* 372, 617-624.
- Hiragun, T., Peng, Z., Beaven, M. A., 2005. Dexamethasone up-regulates the inhibitory adaptor protein Dok-1 and suppresses downstream activation of the mitogen-activated protein kinase pathway in antigen-stimulated RBL-2H3 mast cells. *Mol. Pharmacol.* 67, 598-603.
- Hiragun, T., Peng, Z., Beaven, M. A., 2006. Dexamethasone negatively regulates Syk in mast cells by up-regulating SRC-like adaptor protein. *J. Immunol.* 177, 2047-2050.
- Hodge, S., Hodge, G., Flower, R., Han, P., 1999. Methyl-prednisolone up-regulates monocyte interleukin-10 production in stimulated whole blood. *Scand. J. Immunol.* 49, 548-553.
- Hoffmann, A., Leung, T. H., Baltimore, D., 2003. Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. *EMBO J.* 22, 5530-5539.
- Hofmann, T. G., Hehner, S. P., Bacher, S., Droge, W., Schmitz, M. L., 1998. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. *FEBS Lett.* 441, 441-446.
- Hofmann, T. G., Schmitz, M. L., 2002. The promoter context determines mutual repression or synergism between NF-kappaB and the glucocorticoid receptor. *Biol. Chem.* 383, 1947-1951.
- Horie-Inoue, K., Takayama, K., Bono, H. U., Ouchi, Y., Okazaki, Y., Inoue, S., 2006. Identification of novel steroid target genes through the combination of bioinformatics and functional analysis of hormone response elements. *Biochem. Biophys. Res. Commun.* 339, 99-106.
- Hulley, P. A., Conradie, M. M., Langeveldt, C. R., Hough, F. S., 2002. Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. *Bone* 31, 220-229.

- Imai, E., Stromstedt, P. E., Quinn, P. G., Carlstedt-Duke, J., Gustafsson, J. A., Granner, D. K., 1990. Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. *Mol. Cell. Biol.* 10, 4712-4719.
- Imasato, A., Desbois-Mouthon, C., Han, J., Kai, H., Cato, A. C., Akira, S., Li, J. D., 2002. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable *Haemophilus influenzae*-induced expression of toll-like receptor 2. *J. Biol. Chem.* 277, 47444-47450.
- Ing, N. H., 2005. Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. *Biol. Reprod.* 72, 1290-1296.
- Ip, Y. T., Davis, R. J., 1998. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. *Curr. Opin. Cell Biol.* 10, 205-219.
- Ishmael, F.T., Fang, X., Heller, N., Fan, J., Blackshear, P. J., Atasoy, U., Cheadle, C., Stellato, C., 2007. Role of the RNA-binding protein tristetruprolin (TTP) in glucocorticoid (GC)-mediated gene regulation. *J. Allergy Clin. Immunol.* 119, S134.
- Issa, R., Xie, S., Khorasani, N., Sukkar, M., Adcock, I. D., Lee, K-Y., Chung, K. F. Corticosteroid inhibition of GRO- α via mitogen-activated kinase phosphatase-1 (MKP-1) in airway smooth muscle cells. *J. Immunol.* In press.
- Itani, O. A., Auerbach, S. D., Husted, R. F., Volk, K. A., Ageloff, S., Knepper, M. A., Stokes, J. B., Thomas, C. P., 2002. Glucocorticoid-stimulated lung epithelial Na(+) transport is associated with regulated ENaC and sgk1 expression. *Am. J. Physiol. Lung Cell Mol. Physiol.* 282, L631-641.
- Jalonen, U., Lahti, A., Korhonen, R., Kankaanranta, H., Moilanen, E., 2005. Inhibition of tristetruprolin expression by dexamethasone in activated macrophages. *Biochem. Pharmacol.* 69, 733-740.
- Janka-Junttila, M., Moilanen, E., Hasala, H., Zhang, X., Adcock, I., Kankaanranta, H., 2006. The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils. *J. Inflamm. (Lond)* 3, 10.
- Jiang, X., Norman, M., Roth, L., Li, X., 2004. Protein-DNA array-based identification of transcription factor activities regulated by interaction with the glucocorticoid receptor. *J. Biol. Chem.* 279, 38480-38485.
- John, C. D., Sahni, V., Mehet, D., Morris, J. F., Christian, H. C., Perretti, M., Flower, R. J., Solito, E., Buckingham, J. C., 2007. Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides. *FASEB J.*
- Kabotyanski, E. B., Huetter, M., Xian, W., Rijnkels, M., Rosen, J. M., 2006. Integration of prolactin and glucocorticoid signaling at the beta-casein promoter and enhancer by ordered recruitment of specific transcription factors and chromatin modifiers. *Mol. Endocrinol.* 20, 2355-2368.
- Kallwellis-Opara, A., Zaho, X., Zimmermann, U., Unterman, T. G., Walther, R., Schmoll, D., 2003. Characterization of cis-elements mediating the stimulation of glucose-6-phosphate transporter promoter activity by glucocorticoids. *Gene* 320, 59-66.
- Kang, B. N., Tirumurugan, K. G., Deshpande, D. A., Amrani, Y., Panettieri, R. A., Walseth, T. F., Kannan, M. S., 2006. Transcriptional regulation of CD38 expression by tumor necrosis factor- α in human airway smooth muscle cells: role of NF- κ B and sensitivity to glucocorticoids. *FASEB J.* 20, 1000-1002.
- Karagiannidis, C., Akdis, M., Holopainen, P., Woolley, N. J., Hense, G., Ruckert, B., Mantel, P. Y., Menz, G., Akdis, C. A., Blaser, K., et al., 2004. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. *J. Allergy Clin. Immunol.* 114, 1425-1433.
- Kassel, O., Cato, A. C., 2002. Mast cells as targets for glucocorticoids in the treatment of allergic disorders. *Ernst Schering Res. Found. Workshop* 153-176.

- Kassel, O., Sancono, A., Kratzschmar, J., Kreft, B., Stassen, M., Cato, A. C., 2001. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. *EMBO J.* 20, 7108-7116.
- Klement, J. F., Rice, N. R., Car, B. D., Abbondanzo, S. J., Powers, G. D., Bhatt, P. H., Chen, C. H., Rosen, C. A., Stewart, C. L., 1996. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. *Mol. Cell. Biol.* 16, 2341-2349.
- Kontoyiannis, D., Pasparakis, M., Pizarro, T.T., Cominelli, F., Kollias, G., 1999. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. *Immunity* 10, 387-398.
- Koprak, S., Staruch, M. J., Dumont, F. J., 1999. A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. *Cell. Immunol.* 192, 87-95.
- Kordula, T., Travis, J., 1996. The role of Stat and C/EBP transcription factors in the synergistic activation of rat serine protease inhibitor-3 gene by interleukin-6 and dexamethasone. *Biochem. J.* 313, 1019-1027.
- Korhonen, R., Lahti, A., Hamalainen, M., Kankaanranta, H., Moilanen, E., 2002. Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages. *Mol. Pharmacol.* 62, 698-704.
- Kracht, M., Saklatvala, J., 2002. Transcriptional and post-transcriptional control of gene expression in inflammation. *Cytokine* 20, 91-106.
- Kurata, S., Yamamoto, N., 1999. Glucocorticoid can reduce the transcriptional activation of HIV-1 promoter through the reduction of active NF-kappaB. *J. Cell. Biochem.* 76, 13-19.
- Kurokouchi, K., Kambe, F., Kikumori, T., Sakai, T., Sarkar, D., Ishiguro, N., Iwata, H., Seo, H., 2000. Effects of glucocorticoids on tumor necrosis factor alpha-dependent activation of nuclear factor kappaB and expression of the intercellular adhesion molecule 1 gene in osteoblast-like ROS17/2.8 cells. *J. Bone Miner. Res.* 15, 1707-1715.
- Kwon, H. S., Huang, B., Unterman, T. G., Harris, R. A., 2004. Protein kinase B-alpha inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors. *Diabetes* 53, 899-910.
- Kwon, O. J., Au, B. T., Collins, P. D., Baraniuk, J. N., Adcock, I. M., Chung, K. F., Barnes, P. J., 1994. Inhibition of interleukin-8 expression by dexamethasone in human cultured airway epithelial cells. *Immunology* 81, 389-394.
- Lang, R., Hammer, M., Mages, J., 2006. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. *J. Immunol.* 177, 7497-7504.
- Lasa, M., Abraham, S. M., Boucheron, C., Saklatvala, J., Clark, A. R., 2002. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. *Mol. Cell. Biol.* 22, 7802-7811.
- Lasa, M., Brook, M., Saklatvala, J., Clark, A. R., 2001. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. *Mol. Cell. Biol.* 21, 771-780.
- Lechner, J., Welte, T., Doppler, W., 1997. Mechanism of interaction between the glucocorticoid receptor and Stat5: role of DNA-binding. *Immunobiology* 198, 112-123.
- Leclerc, N., Luppen, C. A., Ho, V. V., Nagpal, S., Hacia, J. G., Smith, E., Frenkel, B., 2004. Gene expression profiling of glucocorticoid-inhibited osteoblasts. *J. Mol. Endocrinol.* 33, 175-193.
- Lee, S. W., Tsou, A. P., Chan, H., Thomas, J., Petrie, K., Eugui, E. M., Allison, A. C., 1988. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. *Proc. Natl. Acad. Sci. U. S. A.* 85, 1204-1208.

- Lerner, L., Henriksen, M. A., Zhang, X., Darnell, J. E., Jr., 2003. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. *Genes Dev.* 17, 2564-2577.
- Leung, T. H., Hoffmann, A., Baltimore, D., 2004. One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers. *Cell* 118, 453-464.
- Li, L. B., Leung, D. Y., Hall, C. F., Goleva, E., 2006. Divergent expression and function of glucocorticoid receptor {beta} in human monocytes and T cells. *J. Leukoc. Biol.*
- Liden, J., Rafter, I., Truss, M., Gustafsson, J. A., Okret, S., 2000. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. *Biochem. Biophys. Res. Commun.* 273, 1008-1014.
- Lim, L. H., Pervaiz, S., 2007. Annexin 1: the new face of an old molecule. *FASEB J.*
- Liu, J., Zhu, X., Myo, S., Lambertino, A. T., Xu, C., Boetticher, E., Munoz, N. M., Sano, M., Cordoba, M., Learoyd, J., et al., 2005. Glucocorticoid-induced surface expression of annexin 1 blocks beta2-integrin adhesion of human eosinophils to intercellular adhesion molecule 1 surrogate protein. *J. Allergy Clin. Immunol.* 115, 493-500.
- Liu, Y., Shepherd, E. G., Nelin, L. D., 2007. MAPK phosphatases - regulating the immune response. *Nat. Rev. Immunol.* 7, 202-212.
- Luecke, H. F., Yamamoto, K. R., 2005. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. *Genes Dev.* 19, 1116-1127.
- Lykke-Andersen, J., Wagner, E., 2005. Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1. *Genes Dev.* 19, 351-361.
- Ma, W., Gee, K., Lim, W., Chambers, K., Angel, J. B., Kozlowski, M., Kumar, A., 2004. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. *J. Immunol.* 172, 318-330.
- Ma, W., Lim, W., Gee, K., Aucoin, S., Nandan, D., Kozlowski, M., Diaz-Mitoma, F., Kumar, A., 2001. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. *J. Biol. Chem.* 276, 13664-13674.
- Mak, J. C., Nishikawa, M., Barnes, P. J., 1995. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. *Am. J. Physiol.* 268, L41-46.
- Manoli, I., Le, H., Alesci, S., McFann, K. K., Su, Y. A., Kino, T., Chrousos, G. P., Blackman, M. R., 2005. Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells. *FASEB J.* 19, 1359-1361.
- Marchant, A., Amraoui, Z., Gueydan, C., Bruyns, C., Le Moine, O., Vandenabeele, P., Fiers, W., Buurman, W. A., Goldman, M., 1996. Methylprednisolone differentially regulates IL-10 and tumour necrosis factor (TNF) production during murine endotoxaemia. *Clin. Exp. Immunol.* 106, 91-96.
- Marinovic, A. C., Zheng, B., Mitch, W. E., Price, S. R., 2002. Ubiquitin (UbC) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1. *J. Biol. Chem.* 277, 16673-16681.
- Matsuno, F., Chowdhury, S., Gotoh, T., Iwase, K., Matsuzaki, H., Takatsuki, K., Mori, M., Takiguchi, M., 1996. Induction of the C/EBP beta gene by dexamethasone and glucagon in primary-cultured rat hepatocytes. *J. Biochem. (Tokyo)* 119, 524-532.
- Matyszak, M. K., Citterio, S., Rescigno, M., Ricciardi-Castagnoli, P., 2000. Differential effects of corticosteroids during different stages of dendritic cell maturation. *Eur. J. Immunol.* 30, 1233-1242.

- Michel, S. L., Guerrierio, A. L., Berg, J. M., 2003. Selective RNA binding by a single CCCH zinc-binding domain from Nup475 (Tristetraprolin). *Biochemistry* 42, 4626-4630.
- Mitchell, J., Noisin, E., Hall, R., O'Brien, R., Imai, E., Granner, D., 1994. Integration of multiple signals through a complex hormone response unit in the phosphoenolpyruvate carboxykinase gene promoter. *Mol. Endocrinol.* 8, 585-594.
- Mittelstadt, P. R., Ashwell, J. D., 2001. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. *J. Biol. Chem.* 276, 29603-29610.
- Morin, B., Zhu, C., Woodcock, G. R., Li, M., Woodward, R. N., Nichols, L. A., Holland, L. J., 2000. The binding site for *Xenopus* glucocorticoid receptor accessory factor and a single adjacent half-GRE form an independent glucocorticoid response unit. *Biochemistry* 39, 12234-12242.
- Mozo, L., Suarez, A., Gutierrez, C., 2004. Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes. *Clin. Exp. Allergy* 34, 406-412.
- Mukaida, N., Morita, M., Ishikawa, Y., Rice, N., Okamoto, S., Kasahara, T., Matsushima, K., 1994. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. *J. Biol. Chem.* 269, 13289-13295.
- Mukaida, N., Zachariae, C. C., Gusella, G. L., Matsushima, K., 1991. Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor. *J. Immunol.* 146, 1212-1215.
- Mullick, J., Anandatheerthavarada, H. K., Amuthan, G., Bhagwat, S. V., Biswas, G., Camasamudram, V., Bhat, N. K., Reddy, S. E., Rao, V., Avadhani, N. G., 2001. Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter. *J. Biol. Chem.* 276, 18007-18017.
- Nakae, J., Kitamura, T., Silver, D. L., Accili, D., 2001. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. *J. Clin. Invest.* 108, 1359-1367.
- Neumann, D., Kollewe, C., Martin, M. U., Boraschi, D., 2000. The membrane form of the type II IL-1 receptor accounts for inhibitory function. *J. Immunol.* 165, 3350-3357.
- Newton, R., 2000. Molecular mechanisms of glucocorticoid action: what is important? *Thorax* 55, 603-613.
- Newton, R., Seybold, J., Kuitert, L. M., Bergmann, M., Barnes, P. J., 1998. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. *J. Biol. Chem.* 273, 32312-32321.
- Nimah, M., Zhao, B., Denenberg, A. G., Bueno, O., Molkentin, J., Wong, H. R., Shanley, T. P., 2005. Contribution of MKP-1 regulation of p38 to endotoxin tolerance. *Shock* 23, 80-87.
- Nishio, Y., Isshiki, H., Kishimoto, T., Akira, S., 1993. A nuclear factor for interleukin-6 expression (NF-IL6) and the glucocorticoid receptor synergistically activate transcription of the rat alpha 1-acid glycoprotein gene via direct protein-protein interaction. *Mol. Cell. Biol.* 13, 1854-1862.
- Nissen, R. M., Yamamoto, K. R., 2000. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. *Genes Dev.* 14, 2314-2329.
- Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al., 2005. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. *Cell* 122, 707-721.
- Ogilvie, R. L., Abelson, M., Hau, H. H., Vlasova, I., Blackshear, P. J., Bohjanen, P. R., 2005. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. *J. Immunol.* 174, 953-961.
- Onda, K., Nagashima, M., Kawakubo, Y., Inoue, S., Hirano, T., Oka, K., 2006. Mitogen-activated protein kinase kinase 1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors sensitize

- reduced glucocorticoid response mediated by TNF α in human epidermal keratinocytes (HaCaT). *Biochem. Biophys. Res. Commun.* 351, 266-272.
- Ono, K., Han, J., 2000. The p38 signal transduction pathway: activation and function. *Cell Signal* 12, 1-13.
- Ou, X. M., Chen, K., Shih, J. C., 2006. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. *J. Biol. Chem.* 281, 21512-21525.
- Parente, L., Solito, E., 2004. Annexin 1: more than an anti-phospholipase protein. *Inflamm Res* 53, 125-132.
- Penner, G., Gang, G., Sun, X., Wray, C., Hasselgren, P. O., 2002. C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 282, R439-444.
- Peppel, K., Vinci, J. M., Baglioni, C., 1991. The AU-rich sequences in the 3' untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids. *J. Exp. Med.* 173, 349-355.
- Perretti, M., Gavins, F. N., 2003. Annexin 1: an endogenous anti-inflammatory protein. *News Physiol. Sci.* 18, 60-64.
- Perretti, M., Getting, S. J., Solito, E., Murphy, P. M., Gao, J. L., 2001. Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. *Am. J. Pathol.* 158, 1969-1973.
- Phillips, J. E., Gersbach, C. A., Wojtowicz, A. M., Garcia, A. J., 2006. Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation. *J. Cell Sci.* 119, 581-591.
- Phillips, K., Kedersha, N., Shen, L., Blackshear, P. J., Anderson, P., 2004. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor α , cyclooxygenase 2, and inflammatory arthritis. *Proc. Natl. Acad. Sci. U. S. A.* 101, 2011-2016.
- Piemonti, L., Monti, P., Allavena, P., Sironi, M., Soldini, L., Leone, B. E., Socci, C., Di Carlo, V., 1999. Glucocorticoids affect human dendritic cell differentiation and maturation. *J. Immunol.* 162, 6473-6481.
- Poon, M., Liu, B., Taubman, M. B., 1999. Identification of a novel dexamethasone-sensitive RNA-destabilizing region on rat monocyte chemoattractant protein 1 mRNA. *Mol. Cell. Biol.* 19, 6471-6478.
- Pousset, F., Cremona, S., Dantzer, R., Kelley, K. W., Parnet, P., 2001. Dexamethasone up-regulates type II IL-1 receptor in mouse primary activated astrocytes. *J. Neurochem.* 76, 901-909.
- Pruett, S. B., Fan, R., Zheng, Q., 2003. Characterization of glucocorticoid receptor translocation, cytoplasmic I κ B, nuclear NF κ B, and activation of NF κ B in T lymphocytes exposed to stress-inducible concentrations of corticosterone in vivo. *Int. Immunopharmacol.* 3, 1-16.
- Quan, N., He, L., Lai, W., Shen, T., Herkenham, M., 2000. Induction of I κ B α mRNA expression in the brain by glucocorticoids: a negative feedback mechanism for immune-to-brain signaling. *J. Neurosci.* 20, 6473-6477.
- Ramdas, J., Harmon, J. M., 1998. Glucocorticoid-induced apoptosis and regulation of NF- κ B activity in human leukemic T cells. *Endocrinology* 139, 3813-3821.
- Ramos, R. A., Nishio, Y., Maiyar, A. C., Simon, K. E., Ridder, C. C., Ge, Y., Firestone, G. L., 1996. Glucocorticoid-stimulated CCAAT/enhancer-binding protein α expression is required for steroid-induced G1 cell cycle arrest of minimal-deviation rat hepatoma cells. *Mol. Cell. Biol.* 16, 5288-5301.
- Ray, K. P., Farrow, S., Daly, M., Talabot, F., Searle, N., 1997. Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor α , and inhibition by glucocorticoids. *Biochem. J.* 328 (Pt 2), 707-715.

- Rea, D., van Kooten, C., van Meijgaarden, K. E., Ottenhoff, T. H., Melief, C. J., Offringa, R., 2000. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. *Blood* 95, 3162-3167.
- Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al., 1998. DNA binding of the glucocorticoid receptor is not essential for survival. *Cell* 93, 531-541.
- Reichardt, H. M., Tuckermann, J. P., Gottlicher, M., Vujic, M., Weih, F., Angel, P., Herrlich, P., Schutz, G., 2001. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. *EMBO J.* 20, 7168-7173.
- Rhen, T., Cidlowski, J. A., 2005. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. *N. Engl. J. Med.* 353, 1711-1723.
- Riccardi, C., Bruscoli, S., Ayroldi, E., Agostini, M., Migliorati, G., 2001. GILZ, a glucocorticoid hormone induced gene, modulates T lymphocytes activation and death through interaction with NF-kB. *Adv. Exp. Med. Biol.* 495, 31-39.
- Ristimaki, A., Narko, K., Hla, T., 1996. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. *Biochem. J.* 318, 325-331.
- Rogatsky, I., Ivashkiv, L. B., 2006. Glucocorticoid modulation of cytokine signaling. *Tissue Antigens* 68, 1-12.
- Rogatsky, I., Wang, J. C., Derynck, M. K., Nonaka, D. F., Khodabakhsh, D. B., Haqq, C. M., Darimont, B. D., Garabedian, M. J., Yamamoto, K. R., 2003. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. *Proc. Natl. Acad. Sci. U. S. A.* 100, 13845-13850.
- Rosen, J. M., Zahnow, C., Kazansky, A., Raught, B., 1998. Composite response elements mediate hormonal and developmental regulation of milk protein gene expression. *Biochem. Soc.. Symp.* 63, 101-113.
- Rosen, J., Miner, J. N., 2005. The search for safer glucocorticoid receptor ligands. *Endocr. Rev.* 26, 452-464.
- Roux, J., Pictet, R., Grange, T., 1995. Hepatocyte nuclear factor 3 determines the amplitude of the glucocorticoid response of the rat tyrosine aminotransferase gene. *DNA. Cell. Biol.* 14, 385-396.
- Rozkova, D., Horvath, R., Bartunkova, J., Spisek, R., 2006. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. *Clin. Immunol.*
- Saccani, S., Pantano, S., Natoli, G., 2002. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. *Nat. Immunol.* 3, 69-75.
- Salojin, K. V., Owusu, I. B., Millerchip, K. A., Potter, M., Platt, K. A., Oravec, T., 2006. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. *J. Immunol.* 176, 1899-1907.
- Sassi, H., Pictet, R., Grange, T., 1998. Glucocorticoids are insufficient for neonatal gene induction in the liver. *Proc. Natl. Acad. Sci. U. S. A.* 95, 5621-5625.
- Savoldi, G., Fenaroli, A., Ferrari, F., Rigaud, G., Albertini, A., Di Lorenzo, D., 1997. The glucocorticoid receptor regulates the binding of C/EPBbeta on the alpha-1-acid glycoprotein promoter in vivo. *DNA. Cell. Biol.* 16, 1467-1476.
- Sayegh, R., Auerbach, S. D., Li, X., Loftus, R. W., Husted, R. F., Stokes, J. B., Thomas, C. P., 1999. Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5'-flanking region of the human epithelial sodium channel alpha subunit gene. *J. Biol. Chem.* 274, 12431-12437.

- Schacke, H., Docke, W. D., Asadullah, K., 2002. Mechanisms involved in the side effects of glucocorticoids. *Pharmacol. Ther.* 96, 23-43.
- Schacke, H., Rehwinkel, H., Asadullah, K., 2005. Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. *Curr. Opin. Investig. Drugs* 6, 503-507.
- Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., Baldwin, A. S., Jr., 1995a. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. *Science* 270, 283-286.
- Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A., Baldwin, A. S., Jr., 1995b. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. *Mol. Cell. Biol.* 15, 943-953.
- Schleimer, R. P., 2004. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. *Proc. Am. Thorac. Soc.* 1, 222-230.
- Shames, B. D., Meldrum, D. R., Selzman, C. H., Pulido, E. J., Cain, B. S., Banerjee, A., Harken, A. H., Meng, X., 1998. Increased levels of myocardial IkappaB-alpha protein promote tolerance to endotoxin. *Am. J. Physiol.* 275, H1084-1091.
- Shi, X. M., Blair, H. C., Yang, X., McDonald, J. M., Cao, X., 2000. Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. *J. Cell Biochem.* 76, 518-527.
- Smoak, K., Cidlowski, J. A., 2006. Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. *Mol. Cell. Biol.* 26, 9126-9135.
- Solito, E., Mulla, A., Morris, J. F., Christian, H. C., Flower, R. J., Buckingham, J. C., 2003. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. *Endocrinology* 144, 1164-1174.
- Sosinowski, T., Pandey, A., Dixit, V. M., Weiss, A., 2000. Src-like adaptor protein (SLAP) is a negative regulator of T cell receptor signaling. *J. Exp. Med.* 191, 463-474.
- Soundararajan, R., Zhang, T. T., Wang, J., Vandewalle, A., Pearce, D., 2005. A novel role for glucocorticoid-induced leucine zipper protein in epithelial sodium channel-mediated sodium transport. *J. Biol. Chem.* 280, 39970-39981.
- Stafford, J. M., Wilkinson, J. C., Beechem, J. M., Granner, D. K., 2001. Accessory factors facilitate the binding of glucocorticoid receptor to the phosphoenolpyruvate carboxykinase gene promoter. *J. Biol. Chem.* 276, 39885-39891.
- Staples, K. J., Bergmann, M. W., Barnes, P. J., Newton, R., 2003. Evidence for post-transcriptional regulation of interleukin-5 by dexamethasone. *Immunology* 109, 527-535.
- Stellato, C., 2004. Post-transcriptional and nongenomic effects of glucocorticoids. *Proc. Am. Thorac. Soc.* 1, 255-263.
- Stellato, C., Matsukura, S., Fal, A., White, J., Beck, L. A., Proud, D., Schleimer, R. P., 1999. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. *J. Immunol.* 163, 5624-5632.
- Stelmach, I., Jerzynska, J., Kuna, P., 2002. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. *Clin. Exp. Allergy* 32, 264-269.
- Stocklin, E., Wissler, M., Gouilleux, F., Groner, B., 1996. Functional interactions between Stat5 and the glucocorticoid receptor. *Nature* 383, 726-728.
- Stoecklin, E., Wissler, M., Schaetzle, D., Pfizner, E., Groner, B., 1999. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. *J. Steroid Biochem. Mol. Biol.* 69, 195-204.

- Stoecklin, G., Stubbs, T., Kedersha, N., Wax, S., Rigby, W. F., Blackwell, T. K., Anderson, P., 2004. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. *EMBO J.* 23, 1313-1324.
- Stojadinovic, O., Lee, B., Vouthounis, C., Vukelic, S., Pastar, I., Blumenberg, M., Brem, H., Tomic-Canic, M., 2006. Novel genomic effects of glucocorticoids in epidermal keratinocytes: Inhibition of apoptosis, IFN γ pathway and wound healing along with promotion of terminal differentiation. *J. Biol. Chem.*
- Stokes, J. B., Sigmund, R. D., 1998. Regulation of rENaC mRNA by dietary NaCl and steroids: organ, tissue, and steroid heterogeneity. *Am. J. Physiol.* 274, C1699-1707.
- Strahle, U., Schmid, W., Schutz, G., 1988. Synergistic action of the glucocorticoid receptor with transcription factors. *EMBO J.* 7, 3389-3395.
- Subramaniam, N., Champion, J., Rafter, I., Okret, S., 2003. Cross-talk between glucocorticoid and retinoic acid signals involving glucocorticoid receptor interaction with the homoeodomain protein Pbx1. *Biochem. J.* 370, 1087-1095.
- Swanek, J. L., Cobb, M. H., Geppert, T. D., 1997. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. *Mol. Cell. Biol.* 17, 6274-6282.
- Tabardel, Y., Duchateau, J., Schmartz, D., Marecaux, G., Shahla, M., Barvais, L., Leclerc, J. L., Vincent, J. L., 1996. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. *Surgery* 119, 76-80.
- Takeda, T., Kurachi, H., Yamamoto, T., Nishio, Y., Nakatsuji, Y., Morishige, K., Miyake, A., Murata, Y., 1998. Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. *J. Endocrinol.* 159, 323-330.
- Taylor, G. A., Carballo, E., Lee, D. M., Lai, W. S., Thompson, M. J., Patel, D. D., Schenkman, D. I., Gilkeson, G. S., Broxmeyer, H. E., Haynes, B. F., et al., 1996. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. *Immunity* 4, 445-454.
- Theodosiou, A., Ashworth, A., 2002. MAP kinase phosphatases. *Genome Biol.* 3, REVIEWS3009.
- Thiele, K., Bierhaus, A., Autschbach, F., Hofmann, M., Stremmel, W., Thiele, H., Ziegler, R., Nawroth, P. P., 1999. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. *Gut* 45, 693-704.
- Tobler, A., Meier, R., Seitz, M., Dewald, B., Baggiolini, M., Fey, M. F., 1992. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. *Blood* 79, 45-51.
- Toh, M. L., Yang, Y., Leech, M., Santos, L., Morand, E. F., 2004. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids. *Arthritis Rheum.* 50, 3118-3128.
- Tran, T., Fernandes, D. J., Schuliga, M., Harris, T., Landells, L., Stewart, A. G., 2005. Stimulus-dependent glucocorticoid-resistance of GM-CSF production in human cultured airway smooth muscle. *Br. J. Pharmacol.* 145, 123-131.
- Tronche, F., Opherk, C., Moriggl, R., Kellendonk, C., Reimann, A., Schwake, L., Reichardt, H. M., Stangl, K., Gau, D., Hoefflich, A., et al., 2004. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. *Genes Dev.* 18, 492-497.
- Tseng, Y. T., Stabila, J. P., Nguyen, T. T., McGonnigal, B. G., Waschek, J. A., Padbury, J. F., 2001. A novel glucocorticoid regulatory unit mediates the hormone responsiveness of the beta1-adrenergic receptor gene. *Mol. Cell. Endocrinol.* 181, 165-178.

- Tuckermann, J. P., Reichardt, H. M., Arribas, R., Richter, K. H., Schutz, G., Angel, P., 1999. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. *J. Cell Biol.* 147, 1365-1370.
- Vanden Berghe, W., Francesconi, E., De Bosscher, K., Resche-Rigon, M., Haegeman, G., 1999. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. *Mol. Pharmacol.* 56, 797-806.
- Vayssiere, B. M., Dupont, S., Choquart, A., Petit, F., Garcia, T., Marchandeu, C., Gronemeyer, H., Resche-Rigon, M., 1997. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. *Mol. Endocrinol.* 11, 1245-1255.
- Verhoef, C. M., van Roon, J. A., Vianen, M. E., Lafeber, F. P., Bijlsma, J. W., 1999. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. *Ann. Rheum. Dis.* 58, 49-54.
- Vermeulen, L., De Wilde, G., Damme, P. V., Vanden Berghe, W., Haegeman, G., 2003. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). *EMBO J.* 22, 1313-1324.
- Vital, A. L., Goncalo, M., Cruz, M. T., Figueiredo, A., Duarte, C. B., Lopes, M. C., 2003. Dexamethasone prevents granulocyte-macrophage colony-stimulating factor-induced nuclear factor-kappaB activation, inducible nitric oxide synthase expression and nitric oxide production in a skin dendritic cell line. *Mediators Inflamm.* 12, 71-78.
- Wadgaonkar, R., Pierce, J. W., Somnay, K., Damico, R. L., Crow, M. T., Collins, T., Garcia, J. G. 2004. Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells. *Am. J. Respir. Cell Mol. Biol.* 31, 423-431.
- Walther, A., Riehemann, K., Gerke, V., 2000. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. *Mol. Cell* 5, 831-840.
- Wang, J. C., Derynck, M. K., Nonaka, D. F., Khodabakhsh, D. B., Haqq, C., Yamamoto, K. R., 2004. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. *Proc. Natl. Acad. Sci. U. S. A.* 101, 15603-15608.
- Warne, J. P., John, C. D., Christian, H. C., Morris, J. F., Flower, R. J., Sugden, D., Solito, E., Gillies, G. E., Buckingham, J. C., 2006. Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. *Am. J. Physiol. Endocrinol. Metab.* 291, E1264-1273.
- Williams, L. M., Ricchetti, G., Sarma, U., Smallie, T., Foxwell, B. M., 2004. Interleukin-10 suppression of myeloid cell activation--a continuing puzzle. *Immunology* 113, 281-292.
- Wilusz, C. J., Wormington, M., Peltz, S. W., 2001. The cap-to-tail guide to mRNA turnover. *Nat. Rev. Mol. Cell Biol.* 2, 237-246.
- Wiper-Bergeron, N., Wu, D., Pope, L., Schild-Poulter, C., Hache, R. J., 2003. Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. *EMBO J.* 22, 2135-2145.
- Wissink, S., van Heerde, E. C., van der Burg, B., van der Saag, P. T., 1998. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. *Mol. Endocrinol.* 12, 355-363.
- Worthington, M. T., Pelo, J. W., Sachedina, M. A., Applegate, J. L., Arseneau, K. O., Pizarro, T. T., 2002. RNA binding properties of the AU-rich element-binding recombinant Nup475/TIS11/tristetraprolin protein. *J. Biol. Chem.* 277, 48558-48564.
- Wu, W., Chaudhuri, S., Brickley, D. R., Pang, D., Karrison, T., Conzen, S. D., 2004. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. *Cancer Res.* 64, 1757-1764.

- Wu, W., Pew, T., Zou, M., Pang, D., Conzen, S. D., 2005. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. *J. Biol. Chem.* 280, 4117-4124.
- Wu, W., Zou, M., Brickley, D. R., Pew, T., Conzen, S. D., 2006. Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. *Mol. Endocrinol.* 20, 2304-2314.
- Wu, J. J., Roth, R. J., Anderson, E. J., Hong, E-G., Lee, M-K., Choi, C. S., Neuffer, P. D., Shulman, G. I., Kim, J. K., Bennett, A. M., 2006. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. *Cell Metabolism* 4, 61-73.
- Wyszomierski, S. L., Rosen, J. M., 2001. Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor. *Mol. Endocrinol.* 15, 228-240.
- Yamada, K., Duong, D. T., Scott, D. K., Wang, J. C., Granner, D. K., 1999. CCAAT/enhancer-binding protein beta is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter. *J. Biol. Chem.* 274, 5880-5887.
- Yamanashi, Y., Tamura, T., Kanamori, T., Yamane, H., Nariuchi, H., Yamamoto, T., Baltimore, D., 2000. Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. *Genes Dev.* 14, 11-16.
- Yang, H., Mammen, J., Wei, W., Menconi, M., Evenson, A., Fareed, M., Petkova, V., Hasselgren, P. O., 2005. Expression and activity of C/EBPbeta and delta are upregulated by dexamethasone in skeletal muscle. *J. Cell Physiol.* 204, 219-226.
- Yang, Y. H., Morand, E. F., Getting, S. J., Paul-Clark, M., Liu, D. L., Yona, S., Hannon, R., Buckingham, J. C., Perretti, M., Flower, R. J., 2004. Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. *Arthritis Rheum.* 50, 976-984.
- Yang, Y. H., Toh, M. L., Clyne, C. D., Leech, M., Aeberli, D., Xue, J., Dacumos, A., Sharma, L., Morand, E. F., 2006. Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1. *J. Immunol.* 177, 8148-8153.
- Yang, Y., Hutchinson, P., Morand, E. F., 1999. Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. *Arthritis Rheum.* 42, 1538-1544.
- Yeagley, D., Guo, S., Unterman, T., Quinn, P. G., 2001. Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-1 and phosphoenolpyruvate carboxykinase transcription. Roles of forkhead and insulin response sequences. *J. Biol. Chem.* 276, 33705-33710.
- Yona, S., Buckingham, J. C., Perretti, M., Flower, R. J., 2004. Stimulus-specific defect in the phagocytic pathways of annexin 1 null macrophages. *Br. J. Pharmacol.* 142, 890-898.
- Yona, S., Ward, B., Buckingham, J. C., Perretti, M., Flower, R. J., 2005. Macrophage biology in the Anx-A1-/- mouse. *Prostaglandins Leukot. Essent. Fatty Acids* 72, 95-103.
- Zhang, Z., Jones, S., Hagood, J. S., Fuentes, N. L., Fuller, G. M., 1997. STAT3 acts as a co-activator of glucocorticoid receptor signaling. *J. Biol. Chem.* 272, 30607-30610.
- Zhao, Q., Shepherd, E. G., Manson, M. E., Nelin, L. D., Sorokin, A., Liu, Y., 2005. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. *J. Biol. Chem.* 280, 8101-8108.
- Zhao, Q., Wang, X., Nelin, L. D., Yao, Y., Matta, R., Manson, M. E., Baliga, R. S., Meng, X., Smith, C. V., Bauer, J. A., et al., 2006. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. *J. Exp. Med.* 203, 131-140.

- Zhou, Y., Ling, E-A., Dheen, S. T., 2007. Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. *J. Neurochem.* In press.
- Zitnik, R. J., Whiting, N. L., Elias, J. A., 1994. Glucocorticoid inhibition of interleukin-1-induced interleukin-6 production by human lung fibroblasts: evidence for transcriptional and post-transcriptional regulatory mechanisms. *Am. J. Respir. Cell Mol. Biol.* 10, 643-650.

Figure 1. DUSP1 contributes to anti-inflammatory effects of dex on murine macrophages. Bone marrow-derived macrophages from age- and sex-matched DUSP1^{+/+} and DUSP1^{-/-} mice were pretreated with 1 nM to 1 μ M dex for 4 h then stimulated with 10 ng/ml LPS for 4 h. IL-1 α and CSF2 mRNAs were quantified by ribonuclease protection assay; TNF protein expression was measured by ELISA; COX-2, IL-1 β and ERK proteins in whole cell lysates were detected by western blotting. Adapted from (Abraham et al., 2006).

Figure 2. Mechanisms of side effects and anti-inflammatory effects of GCs. In a simple model (A) GCs transactivate genes A, B and C, which all contribute to GC side effects. GCs transrepress genes X, Y and Z, which all contribute to anti-inflammatory effects. In an amended model (B) there is no clear mechanistic separation between anti-inflammatory effects and side effects. Transactivation of gene C contributes to the anti-inflammatory response, whilst transrepression of gene X contributes to side effects. Transactivation of gene B mediates both anti-inflammatory effects and side effects, depending on the context in which it is expressed. Similarly, transrepression of gene Y can have both therapeutic and harmful consequences.

A **B**